Drug, bio-affecting and body treating compositions inventions 08/06

20060194713 - Methods for treating delirium using glucocorticoid receptor-specific antagonists: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The...

20060194714 - Novel depsipeptides and process for preparing same: The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds....

20060194718 - Method of using lectins for prevention and treatment of oral and alimentary tract disorders: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and...

20060194717 - Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin: Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions....

20060194716 - Polyacid glycopeptide derivatives: Disclosed are derivatives of glycopeptides that are substituted at the C-terminus with a substituent that comprises two or more (e.g. 2, 3, 4, or 5) carboxy (CO2H) groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents....

20060194715 - Proteins encoded by ble genes and antibiotics from the bleomycin family: The present invention provides use of a protein conjugate comprising a “ble” protein, which has specific binding properties. The protein conjugates are capable of binding reversibly to an antibiotic from the bleomycin family, which property is exploited in a variety of immobilisation methods. In preferred aspects of the invention, the...

20060194735 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention...

20060194734 - Cardiac muscle function and manipulation: A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in...

20060194720 - Glp-1 derivatives and transmicosal absorption preparations thereof: The invention relates to a GLP-1 derivative including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and...

20060194729 - Method of promoting natural bypass: An angiogenic factor comprising a mixture of proteins derived from bone. The angiogenic protein mixture is produced by a series of steps that allow the proteins to be kept in solution. The angiogenic mixture of bone proteins is produced by a multi-step process that includes at least one ultrafiltration step,...

20060194724 - Methods and systems for nerve regeneration: An exemplary method of regenerating a nerve within a patient includes implanting a system control unit within the patient and applying a stimulus to the nerve with the system control unit in accordance with one or more control parameters. The stimulus is configured to promote regeneration of the nerve. An...

20060194726 - Methods of treating cartilage defects: The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein....

20060194725 - Methods of treating disease with random copolymers: The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals...

20060194723 - Novel medication treatment and delivery strategies for alzheimer's disease, other disorders with memory impairment, and possible treatment strategies for memory improvement: The present invention is a novel method for medication treatment for Alzheimer's Disease, Mild Cognitive Impairment, Age Associated Memory Impairment, other disorders with memory impairment, and for possible treatment strategies for memory improvement....

20060194731 - Polypeptides: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer....

20060194727 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary...

20060194732 - Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation: Recombinant surfactant protein A and medicament compositions based thereon are useful for the prevention or treatment of pulmonary infection and inflammation....

20060194719 - Stabilized exendin-4 compounds: The present invention disclosed compositions comprising a stabilized Exendin-4 (1-39) and related compounds. The invention describes stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln 13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Disclosed are preferred modifications of deaminated, hydrolyzed, oxidized,...

20060194733 - Substantially non-immunogenic injectable collagen: The invention provides an article of manufacture comprising a substantially non-immunogenic injectable collagen for implantation into humans. The invention further provides methods for preparing injectable collagen material by removing collagen-containing material from a non-human animal; washing in saline and alcohol; subjecting material to cellular disruption treatment; and digesting the material...

20060194728 - Surfactant treatment regimen: Regimens for the therapeutic or prophylactic administration of pulmonary surfactant to infants exhibiting or at risk of developing bronchopulmonary dysplasia are disclosed....

20060194721 - Tissue regeneration: A biocompatible, biodegradable composition for encouraging controlled growth, regeneration or repair of biological tissue or cells, the composition comprising a scaffold, formed from biodegradable and biocompatible material, and a receptor for a growth factor, or a growth factor-binding fragment or homologue thereof, located at or adjacent a surface of the...

20060194730 - Tumor associated antigen peptides and use of same as anti-tumor vaccines: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA),...

20060194722 - Use of calcitonin in osteoarthritis: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans....

20060194737 - Hepta-, octa-and nonapeptides having antiangiogenic activity: Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis....

20060194736 - Polypeptide for the treatment of cancer and a method for preparation thereof: This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu. The...

20060194738 - Cytomodulating peptides for treating interstitial cystitis: The methods and compositions relate to treatment of disorders of the bladder. In particular, the methods provide for treatment of interstitial cystitis and related disorders. The methods further comprise treatment to affect various manifestations associated with interstitial cystitis, including, reducing histamine release, modulating Substance P expression, modulating nerve growth factor...

20060194739 - Nociceptin-based analgesics: The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds...

20060194741 - Dimeric iap inhibitors: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of...

20060194740 - Nod1 as an anti-tumor agent: The invention provides compositions and methods for treating tumors that involve increasing the expression of Nod1 and/or the activity of NOD1....

20060194742 - Pyrane derivatives as both ace- and nep-inhibitors: e

20060194743 - Method for inhibiting acrylamide formation and use thereof: An object of the present invention is to establish a method for actively suppressing the formation of acrylamide, which is formed by heating edible materials at a relatively high temperature, and uses thereof, and to provide more safe compositions such as foods, beverages, cosmetics, pharmaceuticals, and intermediates thereof. The present...

20060194745 - Compounds and methods for inhibiting selectin-mediated function: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids,...

20060194744 - Illudin analogs useful as antitumor agents: m

20060194746 - Method and composition to inhibit infections with helicobacter pylori by intake of procyanidins from type b and c: Methods and compositions, including, foods and beverages, for treating, preventing or ameliorating Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract such as peptic ulcers of the stomach are provided by this disclosure. In one preferred aspect, the method comprises administering to a Helicobacter pylori infected subject a therapeutically effective...

20060194747 - Synergistic insecticidal mixtures: t

20060194748 - Methods for treating disorders induced by h. pylori infections and pharmaceutical compositions for the same: The present invention provides a pharmaceutical composition for the treatment of disorders induced, caused, and/or mediated by Helicobacter pylori infection, as well as methods of treating the same by administering the pharmaceutical composition of the present invention....

20060194749 - Tricyclic-nucleoside prodrugs for treating viral infections: Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus....

20060194753 - Agent for treating leishmania infections: Use of a combination of DNA expression constructs for the production of a remedy for the immunization against infections with leishmaniasis, as well as a corresponding vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract...

20060194750 - Methods and materials for modulating trpc4: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of TRPC4. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TRPC4....

20060194754 - Methods for delivering nucleic acid molecules into cells and assessment thereof: Methods for delivering nucleic acid molecules into cells and methods for measuring nucleic acid delivery into cells and the expression of the nucleic acids are provided. The methods are designed for introduction of large nucleic acid molecules, including artificial chromosomes, into cells, and are practiced in vitro and in vivo....

20060194751 - Streptococcus pyogenes antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes, methods for isolating such antigens and specific uses therefor...

20060194752 - Treatment for renal disease: Methods for treating or preventing renal disease or inducing passive immunity against renal disease by administering polynucleotides encoding MCP-1 or both MCP-1 and RANTES are provided. Compositions containing polynucleotides encoding MCP-1 or both MCP-1 and RANTES are also provided....

20060194755 - Compositions and methods for regulating an immune response in a subject: The present invention relates to compositions and methods for regulating an immune response in a subject, particularly to treat a subject with a tumor, notably a solid tumor, or an infectious disease. Disclosed are methods of regulating the innate immunity in a subject, such as by regulating the activity of...

20060194756 - Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists: The present invention relates to the use of adenosine receptor agonists, preferably A3 receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with under-expression of HIF-1α and/or decreased HIF-1 α activity (e.g., ischemic related disorders). The methods of...

20060194760 - Cosmetic preparations: The invention relates to cosmetic preparations containing (a) water-soluble β-(1,3) glucans, substantially devoid of β-(1,6) links, and (b) chitosans. The agents are suitable for hair care and personal hygiene and can also be used for sun protection....

20060194758 - Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and dydrogels thus obtained: A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing...

20060194757 - Cystitis treatment with high dose chondroitin sulfate: Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis....

20060194759 - Topical compositions and methods for treating pain and inflammation: A topical composition and method for treating pain and inflammation by administering an effective amount of a topical composition comprising an anti-inflammatory steroid such as hydrocortisone, a topical anesthetic such as lidocaine, menthol, and a medically acceptable carrier into which the forgoing are incorporated. A chondroprotective agent can also be...

20060194762 - Composition comprising an epothilone and methods for producing a composition comprising an epothilone: The present invention concerns methods for the production of pharmaceutical formulations of Epothilones suitable for being administered parenterally, such as intravenously....

20060194761 - Olivetol-cyclodextrin complexes and regio-selective process for preparing delta 9-tetrahydrocannabinol: A cyclodextrin-olivetol derivative complex is provided. The complex effectively blocks reaction at specific carbons to prevent unwanted reactions. A process for preparing a cannabinoid compound is further provided. The process comprises reacting at least one terpenoid with cyclodextrin-olivetol derivative complex to produce the cannabinoid compound....

20060194764 - Biocides based on silanol terminated silanes and siloxanes: A method of destroying target microorganisms comprises the step of contacting at least one target microorganism with at least one low molecular weight silanol end group containing molecule. The silanol containing molecule is selected from silanols (R1R2R3SiOH), siloxanediols HO(R1R2SiO)nH or siloxanols HO(R1R2SiO)nSiR1R2R3, where R1, R2 and R3 are selected from...

20060194763 - N-alkynyl-2-(substituted phenoxy) alkylamides and their use as fungicides: Fungicidal compounds of the general formula (1) wherein X, Y, Z, R1, R2, R3, R4 and R5 have the definitions given in claim 1....

20060194765 - Methods and compositions using oxidized phospholipids: The instant invention provides compositions, e.g., compositions comprising oxidized phospholipids, for the treatment of diseases, disorders and conditions, e.g., cute lung injury syndromes, sepsis, vascular leakage, edema, acute respiratory distress syndrome (ARDS) or acute inflammation....

20060194766 - Combinations comprising anti-epileptic drugs for the treatment of neurological disorders: This invention relates to combinations comprising two anti-epileptics, pharmaceutical compositions comprising such combinations, and the use of such combinations for the preparation of a medicament for the treatment of neurological disorders, esp. epilepsy....

20060194767 - Novel agents for preventing and treating disorders involving modulation of the ryr receptors: and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated...

20060194768 - Thiazole and thiadiazole inhibitors of tyrosine phosphatases: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B....

20060194769 - Small molecules that reduce fungal growth: The present invention relates to methods for reducing the growth of a fungus with an anti-fungal small molecule. Methods for reducing fungal cell growth in a subject with an anti-fungal small molecule and related compositions are provided. Topical lotion formulations of an anti-fungal small molecule and a topical carrier are...

20060194770 - Methods for modulating tumor growth and metastasis: Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided....

20060194771 - Azobenzene derivative compound, particle and method of fabricating the same: (wherein R1 denotes a hydrogen atom, halogen atom, cyano group, amino group, ester group, nitro group, alkyl group, alkoxyl group, cycloalkyl group, or heterocyclic group; m and n each independently denote an integer ranging from 1 to 6; R2 to R9 each independently denote a hydrogen atom or alkyl group;...

20060194772 - Triamide-substituted heterobicyclic compounds: h

20060194773 - Tetracyline compounds having target therapeutic activities: Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described....

20060194774 - Medicament for inhibiting tumour growth: The present invention relates to novel betulinic acid derivatives with increased activity for the treatment of carcinomas and HIV diseases, a method for preparing such novel betulinic acid derivatives as well as their use as pharmaceuticals....

20060194775 - Estradiol metabolites for the treatment of pulmonary hypertension: Methods are provided for the treatment of pulmonary hypertension and other conditions associated therewith. In particular, the methods include treatment of pulmonary hypertension with an estradiol metabolite or alkoxy analogue of an estradiol metabolite. The estradiol metabolite or alkoxy analogue thereof may be associated with biodegradable microparticles or nanoparticles alone...

20060194776 - Compositions and methods for treating tissue ischemia: The present invention generally provides methods for preventing or treating tissue ischemia using CXCR4 antagonists. In one embodiment, the methods include administering to a mammal a therapeutically effective amount of a particular bicylic polyamine to elevate peripheral blood EPCs. The invention has a wide spectrum of applications including reducing or...

20060194777 - Compositions and methods using same for treating amyloid-associated diseases: Compounds having one or more phenol moieties, derivatives thereof, compositions containing same and uses thereof for the treatment of amyloid-associated diseases are provided....

20060194778 - Azacyclic compounds: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment....

20060194780 - Bicyclic piperidine derivatives as melanocortin-4 receptor agonists: Certain novel bicyclic N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual...

20060194781 - Alkyl ether derivatives or salts thereof: wherein each of R1 and R2 represents one or more groups selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an...

20060194779 - 1h-imidazole derivatives as cannabinoid cb2 receptor modulators: e

20060194782 - Pharmacologically active imidazo[4,5-c] pyridines:

20060194783 - Cgrp receptor antagonists: The present invention is directed to compounds of Formula I and Formula II: (where variables R1, R2, R3, R4, R6, A, B, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the...

20060194784 - Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders: Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes....

20060194785 - Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof: One aspect of the present invention relates to spirocyclic compounds. Another aspect of the present invention relates to the use of the spirocyclic compounds as ligands for mammalian G-protein-coupled receptors or sigma receptors. The present invention also relates to methods of modulating the activity of a G-protein-coupled receptor or a...

20060194786 - Process and intermediates for preparing benzazepines: e

20060194787 - Protease inhibitors: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including...

20060194789 - Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof: e

20060194788 - Guanidine derivatives and their use as neuropeptide ff receptor antagonists: The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R′)— or —O— and R′ is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid...

20060194790 - Bridged bicyclic amine derivatives useful as ccr-3 receptor antagonists: are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar1 are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is —C(═O)N(R10)—, —SO2N(R10)—, —N(R11)C(═O)N(R10O)—, —N(R11)SO2N(R10)—, —N(R11)C(═S)N(R10)—, —N(R11)C(═O)—, —N(R11)SO2—,...

20060194791 - Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders: The present invention relates to the use of a racemate of the compound of formula (1) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said...

20060194792 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same....

20060194793 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: c

20060194794 - Triazole compounds useful in therapy:

20060194795 - Platelet adp receptor inhibitors: Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of...

20060194796 - Method of treatment for preventing or reducing tumor growth in the liver of patient: A method of treatment for preventing or reducing tumor growth in liver of a patient includes administering to the patient an effective about of taurolidine, taurultam or a mixture thereof, so as to prevent or reduce the tumor growth in the patient....

20060194797 - Condensed ring compound and use thereof: (wherein all symbols have the same meanings as described hereinbefore). The compound antagonizes cysLT2 and therefore, it is useful as an agent for the prevention and/or treatment of respiratory diseases such as bronchial asthma, bronchial asthma, chronic obstructive pulmonary disease, pneumonectasia, chronic bronchitis, pneumonia (e.g. interstitial pneumonitis etc.), severe acute...

20060194798 - Bicyclic-substituted amines as histamine-3 receptor ligands: h

20060194799 - Novel pyrimidinedione derivatives: Pyrimidinedione derivatives of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them are useful for the treatment of inflammation and immunological diseases....

20060194801 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same: r

20060194800 - Pteridine derivatives as nitric oxide synthase activators: The present invention relates to the use of pteridine derivatives as nitric oxide synthase activators. In particular, the derivatives find use in the treatment of diseases associated with endothelial dysfunction such as cardiovascular diseases....

20060194802 - Phenylamino isothiazole carboxamidines as mek inhibitors: The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones....

20060194803 - 2,4,6-triamino-1,3,5-triazine derivative: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in...

20060194804 - Hiv replication inhibiting pyrimidines and triazines: This invention concerns HIV replication inhibitors of formula (I), The N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them....

20060194805 - Capsaicin receptor agonists: Capsaicin receptor agonists are provided. Such compounds are ligands that may be used to modulate VR1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to capsaicin receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using...

20060194806 - Optically active 5h-pyrrolo [3,4-b] pyrazine derivative, its preparation and pharmaceutical compositions containing same: Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics....

20060194808 - Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate: Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL)....

20060194807 - Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5: Novel pyrazole compounds such as compounds of the formula (I): (where A, A1, A2, B, R11, W, X, Y and Z are as defined herein) in which the pyrazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of...

20060194809 - Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same: There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which...

20060194810 - Methods of treating ischemic related conditions: The present invention relates to methods of treating or preventing ischemia-related (i.e., neural cell hypoxia and/or hypoglycemic) conditions by administering to a patient in need thereof certain thiosemicarbazone compounds. More particularly, the present invention relates to methods of preventing or treating certain ischemia-related conditions, which may include Alzheimer's disease, Parkinson's...

20060194811 - Pyrimidine derivatives: wherein m1 is 0 to 2, n1 is 0 to 4, a1 is from 0 to a substitutable number, R5 represents substituted or unsubstituted lower alkyl, and each R5 may be the same or different when a1 is 2 or more), and Q represents —NR6R7 (wherein R6 and R7 may...

20060194812 - Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same: The present disclosure provides novel pharmaceutical compounds and methods for making the same, novel pharmaceutical dosage forms and methods for making the same, and methods for using said compounds and dosage forms to treat and prevent diseases and/or disorders....

20060194814 - Benzamide compounds: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in...

20060194813 - Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions: R1 to R6 and X are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and...

20060194815 - Methods and compositions for modulating serum cortisol levels: The present invention relates to cortisol-modulating compounds, including but not limited to benzamide and benzoic acid derivatives such as procaine and procaine derivatives, utilized in compositions and methods for treating cortisol-mediated disorders, including but not limited to age-related depression, hypertension, Alzheimer's disease, and acquired immunodeficiency syndrome....

20060194816 - Benzofuran derivatives useful for treating hyper-proliferative disorders: The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders....

20060194817 - N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and...

20060194818 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same....

20060194819 - Activation specific inhibitors of nf-kb and method of treating inflammatory processes in cardio-vascular diseases: A 5H-Thiazolo[3,2]pyrimidine derivative or a salt thereof for use as a medicine, which is represented by the following formula (A): wherein R represents an optionally substituted phenyl or pyridyl group; R4 represents a hydroxyl group, an amino group, a straight chain or branched alkoxy group, a straight chain or branched...

20060194820 - Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof: A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle....

20060194821 - Compounds inhibiting the aggregation of superoxide dismutase-1: The invention is directed to methods of inhibiting the rate at which superoxide dismutse-1 (SOD) aggregates using compounds that stabilize SOD dimers. The methods are useful in the study and therapy of amyotrophic lateral sclerosis. The invention also includes assays that can be used to identify compounds that stabilize dimers...

20060194822 - Treatment for renal fibrosis: The present invention relates to compositions containing quinazolinones. More particularly, the present invention relates to a composition for treatment renal fibrosis, comprising as active ingredient a quinazolinone derivative as herein defined. The currently preferred embodiment is halofuginone, which is now show to slow or prevent progression of renal fibrosis in...

20060194823 - Sulfonamido-macrocycles as tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof: e

20060194824 - Compositions containing pyrimidine derivatives as inhibitors of cox-2:

20060194825 - Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto: Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds having structure (I), including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as...

20060194826 - Pharmaceutical combinations of hydrocodone and naltrexone: Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof....

20060194827 - 5-cycloalkenyl 5h-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds: The present invention relates to methods for modulating processes mediated by progesterone receptor using nonsteroidal compounds and compositions which may be high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and/or antagonists for progesterone receptors....

20060194829 - Therapeutic materials and methods: Disclosed are compositions and methods for treating or preventing mucositis by administering to the patient an FKBP ligand prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof, but in particular, administration of an mTOR inhibitor such as...

20060194828 - Vitamin comprising pyroloquinoline quinone and use thereof: It is an object of the present invention to clarify the biochemical role of pyrroloquinoline quinone (PQQ) in living bodies by identifying an enzyme that uses PQQ as a coenzyme in mammals and then by clarifying the oxidation-reduction reaction, with which PQQ is associated as a coenzyme in living bodies....

20060194830 - Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone): The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone....

20060194831 - Use of n-desmethylclozapine to treat human neuropsychiatric disease: Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease....

20060194833 - Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses: The invention relates to crystalline 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate, E6070, its method of preparation, and its therapeutic uses. Pharmaceutical compositions containing crystalline E6070 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or...

20060194832 - Enantiomer (-) of tenatoprazole and the therapeutic use thereof: The invention relates to enantiomer (−) of tentoprazole. The inventive enantiomer (−) of tenatoprazole, or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications. The enantiomer (−) of tentoprazole can be used for treating digestive pathologies....

20060194834 - Azacyclic compounds: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment....

20060194835 - Compositions and methods for treating or preventing flaviviridae infections: The present disclosure relates generally to compositions having a glucosidase inhibitor (castanospermine or a derivative thereof, such as celgosivir) in combination with adjunctive therapies of compounds that alter immune function (such as interferon) and compounds that alter viral replication (such as nucleoside analogues like ribavirin), which can be used to...

20060194836 - Novel compounds having 4-pyridylalkylthio group as substituent: A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases...

20060194837 - Tetrahydroisoquinoline compounds: Certain tetrahydroisoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases....

20060194840 - Method for treating snoring and sleep apnea with leukotriene antagonists: A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist....

20060194838 - Polymorphic form of montelukast sodium: The invention provides novel polymorphic form of montelukast sodium, as well as methods of using and pharmaceutical compositions containing saud novel form. Also provided are montelukast sodium: acetonitrile solvates, which are intermediates in the formation of crystalline montelukast sodium....

20060194839 - Process for the preparation of montelukast: e

20060194841 - Benzylamine derivative: The invention provides a compound which exhibits satisfactory peroral absorbability and excellent antagonistic activity against NK-1 receptor or NK-2 receptor. The compound is a benzylamine derivative represented by formula (1) or a salt thereof....

20060194842 - Oxyindole derivatives: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal...

20060194843 - 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators:

20060194844 - 2-acylaminothiazole derivative or salt thereof: 2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided....

20060194845 - Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals: A

20060194846 - [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular:

20060194847 - Novel 6-substituted 2-aminopyridine derivatives: There are provided novel compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, L1, L2, L3 and Q are are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The...

20060194848 - Substituted amine derivatives and methods of use: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention...

20060194849 - Fungicidal composition and method for controlling plant diseases: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n...

20060194850 - Novel azole compound: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic...

20060194851 - Benzofuran compound and medicinal composition containing the same: wherein each symbol is as defined in the description, a pharmaceutically acceptable salt thereof and the like. The compound of the present invention has superior leukotriene inhibitory action, BLT2 competitive inhibitory action, BLT2 blocking action, action for the prophylaxis or treatment of allergy, action for the prophylaxis or treatment of...

20060194852 - Glutaminyl based dpiv inhibitors: e

20060194853 - Alkyl benzamides: The present invention relates to alkyl derivatives of nitazoxanide and tizoxanide and isomers thereof. More specifically, the present invention is directed to compounds possessing anti-parasitic, antibacterial, antiviral and antifungal activities, and to methods of treatment and/or prevention of parasitic, bacterial, viral and/or fungal diseases in humans and animals using said...

20060194854 - New 2-substituted - 1,3-thiazole compounds: The present invention relates to new compounds of formula I, Wherein Y is NR4CONR4, NR4CO, or NR4; R1 is nitro or COR5; R2 is hydrogen or NH2; R3 is C1-6alkyl or C0-6akylaryl wherein C0-6alkylaryl may be substituted by A; R4 is hydrogen; R5 is C1-6alkyl; A is independently selected from...

20060194855 - Method of treating migraines and pharmaceutical compositions: A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine....

20060194857 - Novel heteroaryl derivative: (wherein Ring Z is an optionally substituted heteroaryl, R1 is a carboxyl group or an alkoxycarbonyl group, etc., W1 and W2 are an optionally substituted lower alkylene, Ar1 is an optionally substituted arylene or an optionally substituted heteroarylene, W3 is a single bond, a lower alkylene, a lower alkenylene, etc.,...

20060194858 - Preparation of crude candesartan cilexetil: A process for preparing candesartan cilexetil comprising heating a solution of trityl candesartan cilexetil in a water immiscible solvent in the presence of at least one C1-C4 alcohol and a first portion of water; combining the solution with a second portion of water to obtain a two-phase system; and recovering...

20060194856 - Use of atii antagonist for the treatment or prevention of metabolic syndrome: The present invention relates to the use of an angiotensin II type 1 receptor antagonist alone, or in combination with a metabolically neutral antihypertensive substance, for the prevention and/or treatment of the metabolic syndrome....

20060194859 - Preparation and use of aryl alkyl acid derivatives for the treatment of obesity: This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases....

20060194861 - Cyclooxygenase-2 selective inhibitors, compositions and methods of use: The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a...

20060194860 - Pharmaceutical compositions containing aryl or heteroaryl azolylcarbinol compounds: e

20060194862 - 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists: This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention...

20060194863 - 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation....

20060194864 - Indole derivatives: wherein all symbols represent the same meanings as described in specification. and salts thereof. Since the compound represented by the formula (I) binds and antagonizes to DP receptor, it is useful for the prevention or treatment against the disease such as allergic disorder, diseases accompanied with itching, secondary diseases generated...

20060194865 - G-lactam derivatives as prostaglandin agonists: The present invention relates γ-lactam derivatives, in particular for use as medicaments, as well as pharmaceutical formulations containing such γ-lactam derivatives. Said γ-lactam derivatives are useful in the treatment and/or prevention of asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders....

20060194866 - Methods for treating or preventing cancer using benzopyranone compounds: e

20060194868 - Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and /or congestive heart failure: The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF)....

20060194867 - Process for the preparation of atorvastatin and intermediates: e

20060194869 - Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof: Processes for preparing DNT-base, duloxetine alkyl carbamate, duloxetine-base and duloxetine hydrochloride, are provided. Also provided, are processes for converting DNT-base, duloxetine alkyl carbamate and duloxetine-base into pharmaceutically acceptable salts of duloxetine....

20060194870 - Compound having anti-hcv activity and process for producing the same: (wherein A represents —(CH2)n—, etc.; B represents —(C═O)—, etc.; D represents —(CH2)m—R′, etc.; E represents a hydrogen atom, etc.; G represents —(CH2)p-J, etc.; bond Q represents a single bond or double bond; and R1, R2 and R3 may be the same or different and each represent a hydrogen atom, etc.),...

20060194871 - Heterocyclic mchr1 antagoists: This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11 CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have the formula:...

20060194872 - Diamine derivative, production process therefor and antioxidant: (wherein, R1, R2, R3 and R4 respectively and independently represent a hydrogen atom or a C1-6 alkyl group, and n represents an integer of 1 or 2) and a production process thereof, as well as an antioxidant that contains the compound as its active ingredient, and a kidney disease treatment...

20060194873 - Methods of treating epileptogenesis and epilepsy: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with...

20060194874 - Use of propionyl l-carnitine for the preparation of a medicament for the treatment of glaucoma: Propionyl L-carnitine is used for the treatment of glaucoma and is preferably administrated orally or ophthalmically. Propionyl L-carnitine exhibits an anti-aptoptotic action on the nerve cells of the eye....

20060194875 - Process for preparation of probucol derivatives: o

20060194877 - Creatine hydroxycitric acids salts and methods for their production and use in individuals: Methods of production for Tricreatine Hydroxycitrate are disclosed. Tricreatine hydroxycitrate can be used as supplemental dietary ingredient for the purposes of reducing adiposity, suppression of appetite, improvement of muscle and exercise performance and recovery. The salts are useful in the dietetic, food supplement and food industries....

20060194876 - Substantially pure tolterodine tartrate and process for preparing thereof: The present invention provides substantially pure Tolterodine....

20060194878 - Methods of cardioprotection using dichloroacetate in combination with an inotrope: The present invention provides compositions and methods for maintaining or improving cardiac function by administering a cardioprotective amount of dichloroacetate (DCA) and an inotropic drug. Also provided are dosage protocols and pharmaceutical compositions for use in these methods....

20060194879 - Pharmaceutically useful salts of carboxylic acid derivates: A calcium or a magnesium salt of (2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid....

20060194880 - Method for treating central nervous system disorders: The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound....

20060194881 - Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof: The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a carbamic acid derivative. The invention also concerns...

20060194882 - Method of treating airway diseases with beta-adrenergic inverse agonists: The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat...

20060194883 - Mmp expression inhibitor: An extracellular matrix protease (MMP) is an enzyme which is expressed in the course of tissue generation and differentiation via repeated cell division of a fertilized egg, and is also closely associated with invasion and metastasis of cancer. Degradation of extracellular matrix around cancer cells and in the vascular basal...

20060189511 - Method for cytoprotection through mdm2 and hdm2 inhibition: The present invention is directed to a method of protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class...

20060189512 - Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging: Compositions are disclosed which contain therapeutically effective amounts of phlorizin extract for effecting modification of blood glucose and insulin, for facilitating weight loss, preventing weight gain and for providing beneficial effects in the aging process. Methods of treating animals with phlorizin extract compositions to treat the aforementioned conditions of the...

20060189513 - Lactoferrin in the treatment of diabetes mellitus: The present invention relates to methods of using a composition of lactoferrin for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated hemoglobin (HbA1c)....

20060189514 - Compositions and uses of a galectin for treatment of dry eye syndrome: Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and/or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active...

20060189517 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds....

20060189516 - Method for producing cross-linked hyaluronic acid-protein bio-composites: This invention is concerned with a new method for producing cross-linked hyaluronic acid—protein bio-composites in various shapes. In the present process, a polysaccharide solution and a protein solution are mixed under moderate pH values in presence of salts to form a homogenous solution, which can be processed into various shapes,...

20060189515 - Molecules for transporting a compound across the blood-brain barrier: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting a compound...

20060189519 - Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf): The present invention provides anti-angiogenic derived from pigment epithelium-derived factor (PEDF) pharmaceutical compositions comprising the peptides, and methods of preventing angiogenesis. Such methods are useful in treating angiogenesis-associated disorders and diseases....

20060189535 - Combination treatment using exendins and thiazolidinediones: The present invention relates to methods for treatment and/or prevention of diabetes and diabetes related diseases. More specifically, the methods and uses of the invention pertains to administration of an exendin-4 compound in combination with administration of a thiazolidinedione insulin sensitizer....

20060189526 - Compositions containing an intestinal trefoil peptide and a mucoadhesive: The invention features compositions containing an intestinal trefoil peptide and a mucoadhesive excipient. Such compounds are useful, e.g., for the treatment or prevention of lesions. Compositions containing an intestinal trefoil peptide and a mucoadhesive excipient may be formulated in combination with one or more additional therapeutic agents....

20060189534 - Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same: The present invention is directed to a method of inhibiting at least one of vascular leakage, angiogenesis, inflammation and fibrosis in an animal by administering to the animal an effective amount of a composition, wherein the composition is selected from the group consisting of kallistatin, fragments of kallistatin, analogs or...

20060189525 - Dadd, death activator death domain protein: Polynucleotides encoding DADD protein are also disclosed, along with vectors, host cells, and methods of making DADD protein. Methods of identifying inhibitors of DADD death domain binding and inhibitors identified by such methods are also disclosed....

20060189521 - Human liver regeneration associated protein and the use thereof: This invention provides a novel human liver regeneration associated protein hLRTM4 and the polynucleotide which encodes the hLRTM4 protein. Furthermore, this invention provides a method of preparing and using hLRTM4 protein and its polynucleotides. hLRTM4 protein can be used to treat liver injury, and its antagonists (e.g. antisense nucleic acids...

20060189527 - Methods of treating disease with random copolymers: The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals...

20060189522 - Modification of feeding behaviour: The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure....

20060189529 - Modified human growth hormone: Modified growth hormone polypeptide and uses thereof are provided....

20060189530 - Neuropeptide y receptor y5 and nucleic acid sequences: The present invention provides novel NPY/PYY receptor proteins and the nucleic acid sequence encoding them. The invention is directed to the isolation, characterization, and pharmacological use of these receptors and nucleic acids. In particular, this invention provides human and rat NPY/PYY receptors (which we call the NPY Y5 receptor) and...

20060189528 - Osteoprotegerin variant proteins: The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduce binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant...

20060189524 - Pharmaceutical compositions based on anticholinergics and pegsunercept: The present invention relates to novel pharmaceutical compositions based on anticholinergics and pegsunercept, processes for preparing them and their use in the treatment of respiratory diseases....

20060189518 - Preventing/remedies for cancer: The invention provides prophylactic/therapeutic agent for cancer, etc. More specifically, a compound or its salt inhibiting the activity f a protein having an amino acid sequence, which is the same or substantially the same amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 16, a compound...

20060189533 - Stable pharmaceutical dosage forms of teriparatide: A parathyroid hormone (1-34) (PTH) dosage form is described that is suitable for multi-use administration. A dosage form of parathyroid hormone (1-34) (PTH) comprising an aqueous pharmaceutical formulation for aerosolized intranasal delivery of PTH having a bioavailability of about 5% or greater, wherein the formulation comprises a therapeutically effective amount...

20060189531 - Thrombopoietic compounds: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal....

20060189536 - Treating the effects of nicotine: The invention provides methods and materials for treating the effects of nicotine. In particular, the invention provides methods that involve administering a neurotensin receptor (NTR) agonist to a mammal that has been exposed to nicotine. The NTR agonist typically is administered in an amount effective to diminish or abolish the...

20060189520 - Treatment of diabetes: Compositions and methods are provided for islet neogenesis therapy comprising a member of a group of factors that complement a gastrin/CCK receptor ligand, with formulations, devices and methods for sustained release delivery and for local delivery to target organs....

20060189532 - Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis: Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the calcitonin, calcitonin-like peptides or calcitonin mimetics....

20060189523 - Use of effectors of glutaminyl and glutamate cyclases: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting...

20060189537 - Peptides for detection of antibody to ehrlichia ewingii: The invention provides compositions and methods for the detection and quantification of Ehrlichia ewingii, Ehrlichia ewingii antibodies, antibody fragments, and polypeptides....

20060189539 - Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof: The present invention provides peptides and pharmacologically active compounds including gonadotropin-releasing hormone (GnRH) analogues according to formulas of the invention, wherein the compounds show an antitumour effect. The invention additionally provides compositions including these peptides and compounds....

20060189538 - Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof: The invention relates to anti-microbial and immunostimulatory molecules of the cathelicidin family derived from fish. The invention provides a novel cathelicidin molecule, fragments, derivatives and uses thereof, and nucleic acids encoding the same....

20060189540 - Peptides for diagnostic and therapeutic methods for celiac sprue: Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses....

20060189541 - Methods of treating dry eye disorders: Inhibitors of cytokine synthesis in nonimmune, resident ocular surface cells are useful for treating dry eye disorders and other disorders requiring the wetting of the eye....

20060189543 - Compositions and methods for the treatment of leukemia: A method for the treatment of leukemia by internal administration of a composition including one or more compounds that inhibit cytokines and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier. The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivatives, and...

20060189544 - Integrin-mediated drug targeting: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and αvβ3 integrin antagonist and at the same time the desired intracellular action in...

20060189542 - Preventive or therapeutic composition for viral infectious disease: The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating...

20060189546 - Compounds for treating autoimmune and demyelinating diseases: e

20060189548 - Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture:

20060189545 - Novel chemical entities and methods for their use in treatment of metabolic disorders: Methods and composition for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of novel esterified saccharide compounds to said patient at a level to...

20060189547 - Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use: Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient,...

20060189549 - Chalcone derivatives and their use to treat diseases: d

20060189550 - Immunostimulatory, covalently lipidated oligonucleotides: Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer...

20060189551 - Combination therapies for fungal pathogens: The present invention relates to methods of treating fungal infections with a drug combination: a first compound that inhibits the activity or expression of the protein FKBP12 and a second compound that inhibits the activity or expression of homoserine dehydrogenase. Evidence indicates that dual inhibitors of proteins FKBP12 and homoserine...

20060189552 - Dispenser for dispensing three or more actives: Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife...

20060189558 - Delivery of substances to cells: Aggregates comprising VP22 protein and oligonucleotides or polynucleotides can be used together with a disaggregating agent (simultaneously or sequentially) to treat target cells by delivery of molecules to the cells and/or to prevent cell proliferation and/or to kill cells....

20060189563 - Detection and modulation of iaps and naip for the diagnosis and treatment of proliferative disease: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides....

20060189556 - Dna cancer vaccines: A plurality of DNA cancer vaccines and their uses in treating cancer are disclosed. Genes encoding Mycobacterium bovis bacillus Calmette-Guérin (M. bovis BCG) recombinant antigens and genes encoding interlukin-12 heterodimer were respectively cloned into eukaryotic expression vectors to express the encoded recombinant proteins in mammalian cells in vivo whereby specific...

20060189562 - In vitro-differentiated retinal ganglion cells and method for producing same: In vitro-differentiated retinal ganglion cells can be produced by exposing a mammalian retinal ganglion cell line to a protein kinase inhibitor. The differentiated retinal ganglion cells can be used to identify agents that protect retinal ganglion cells in vivo or in vitro from cell injury (including cell death) and agents...

20060189559 - Method and system for treating hepatitis c: A method and system for treating Hepatitis C includes using an implantable pump and an outlet catheter. A proximal end of the outlet catheter is fluidly connected to an outlet port of the pump. A distal end of the outlet catheter is sized to deliver medication from the pump to...

20060189564 - Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain: Disclosed herein are methods and sequences used to treat pain. Specifically, the methods and sequences include locally administering nucleic acid molecules that suppress the expression of amino acid sequences that encode for pro-inflammatory cytokines and their receptors to treat acute or neuropathic pain associated with sciatica....

20060189560 - Molecular method to augment rna mediated gene silencing: The invention provides for a novel method of augmenting gene silencing via RNA interference (RNAi). Under the invention, RNAi technology is combined with the action of a variant nuclear factor to potently inhibit gene expression. In one embodiment of the invention, the nuclear factor is a variant of a double-stranded...

20060189554 - Nanoparticle-based vaccine delivery system containing adjuvant: A vaccine delivery system comprising adjuvant and nanoparticles comprising an immunogenic agent is provided. A method of immunizing an animal comprising administering a nanoparticle-based vaccine delivery system is also provided....

20060189553 - Nucleic acid injected into hapatic vein lumen and delivered to primate liver: Processes are described for obtaining high levels of gene expression in primates after injection of nucleic acid to the liver via the lumen of the hepatic vein. The described process results in high level of gene expression with transient increases in liver enzymes....

20060189555 - Pyrroles substituted by oligonucleotides: The invention relates to novel pyrrole derivatives of the formula (I) which make it possible to immobilize and address oligonucleotides by electropolymerization. Said invention also relates to thus produced electroactive polymers and to methods for using them for detecting, identifying and dosing analytes in a sampe. (I) wherein R1 is...

20060189557 - Regulation of oncogenes by micrornas: Naturally occurring miRNAs that regulate human oncogenes and methods of use therof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA...

20060189561 - Rnai expression constructs with liver-specific enhancer/promoter: The present invention provides compositions and methods suitable for RNAi specifically in the liver so as to treat diseases or disorders....

20060189565 - Pharmaceutical compositions of ganciclovir: The technical field of the invention relates to pharmaceutical compositions of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) that are stable and contain more than 1% water content. One pharmaceutical composition includes ganciclovir having more than about 1% water content, and one or more pharmaceutically acceptable excipients. The ganciclovir retains at least about 97%...

20060189566 - Muscle building agent and preventive or remedy for muscle weakening: In accordance with the present invention, there can be provided a muscle building agent, a preventive or therapeutic agent for muscle wasting, food and drink or feed for muscle building or for prevention or treatment of muscle wasting, and a food and drink additive or a feed additive for muscle...

20060189572 - Composition for local anesthesia: A composition for local anesthesia which comprises a local anesthetic as an active ingredient and an agent for maintaining anesthetic action selected from the group consisting of acidic mucopolysaccharides such as sodium chondroitin sulfate and cellulose derivatives such as hydroxypropylmethylcellulose, and does not contain catecholamines, which has durability of anesthetic...

20060189567 - Compound having affinity with calcified tissue: The present invention provides a compound excellent in accumulation on calcified tissues and ensuring rapid excretion into urine as well as rapid clearance from blood, useful as a diagnostic agent and a therapeutic agent, etc. The compound is a compound having affinity with a calcified tissue represented by the following...

20060189568 - Use of lipid conjugates in the treatment of infection: This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject....

20060189569 - Use of lipid conjugates in the treatment of infection: This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject....

20060189570 - Use of lipid conjugates in the treatment of infection: This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject....

20060189571 - Use of lipid conjugates in the treatment of infection: This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject....

20060189573 - Solutions and films of glycated chitosan: Preparations containing glycated chitosan in a physiologically compatible carrier are described. Viscoelastic preparations comprise 1.0-12.0 percent by weight of glycated chitosan in an aqueous solution while lower viscosity solutions possess 0.1-0.5 percent by weight glycated chitosan. The otherwise free amino groups of the chitosan polymer are preferably 30-90% glycated and...

20060189574 - Method of treating high plasma cholesterol levels: A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant....

20060189575 - Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels: The present invention is in the field of cholesterol and triglyceride-lowering methods and compositions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside and/or sphingomyelin for lowering the cholesterol and triglyceride levels in a subject and to the use of sphingolipids...

20060189578 - Method for the synthesis of compounds of formula i and their uses thereof: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated...

20060189576 - Substituted vitamin d analogues and their therapeutic uses: The present invention relates to analogues of vitamin D namely 14-epi-2-alkyl-19-nor vitamin D derivatives. Also a general method for the synthesis and the biological activities are described. The general formula is: (I) where R (α or β oriented) represents an alkyl substituent and X part of a typical side chain...

20060189577 - Tyrosine kinase inhibitors: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a substituted pyrrole moiety. The present invention is also related to the pharmaceutically acceptable...

20060189579 - Method of stabilizing ascorbyl phosphate and salts thereof: Ascorbyl phosphate is stabilized against degradation by phosphatases by coating with a lipid....

20060189580 - 1-adamantyl chalcones for the treatment of proliferative disorders: c

20060189581 - Compounds and methods for treating transplant rejection:

20060189582 - Compositions and methods for treatment of disorders of protein aggregation: The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence....

20060189583 - Aryl dicarboxamides: The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular,...

20060189584 - Pharmaceutical combinations: The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy. The combinations comprise a compound of formula (I) or a pharmaceutically acceptable derivative thereof; formula (I), and another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof....

20060189585 - Dosage and method for attaining beneficial levels of vitamin d3: The present invention provides for: (a) an oral dosage of vitamin D3 for humans sufficient to maintain a serum level above a minimally sufficient level and below a toxic level when administered according to a schedule of at least one dosage a week up to at least one dosage a...

20060189586 - Pharmaceutical compositions comprising active vitamin d compounds: Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase...

20060189588 - Process for producing unsaturated fatty acid-containing oils: An edible oil obtained by culturing a microorganism belong to the genus Mortierella subgenus Mortierella in a medium containing a nitrogen source derived from soybean is discussed. The oils obtained have a low 24,25-methylenecholest-5-en-3β-ol content....

20060189587 - Use for budesonide and formoterol: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease....

20060189589 - 2-methylthiazolidine-2,4-dicarboxylic acid and salts thereof for treatment of neurodegenerative diseases: The invention relates to the compounds (2R,4R), (2S,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and (2RS,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and salts of said compounds, the use thereof for the prophylaxis and/or treatment of neurodegenerative diseases, methods for the prophylaxis and/or treatment of neurodegenerative diseases, and pharmaceutical compositions containing said compounds together with physiologically compatible carriers, auxiliary agents,...

20060189590 - Alkaline salts of proton pump inhibitors: The invention relates to alkaline salts of proton pump inhibitors and to medicaments comprising these compounds....

20060189592 - Crystal of 1-methylcarbapenem compound: e

20060189591 - Five-membered heterocyclic derivative: a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor...

20060189593 - Aryl spirohydantoin cgrp receptor antagonists: The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the...

20060189594 - Procedure for preparing a pharmaceutically active compound: e

20060189595 - Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors: A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described...

20060189596 - Bridged bicyclic amine derivatives useful as ccr-3 receptor antagonists: are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar1 are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is —C(═O)N(R10)—, —SO2N(R10)—, —N(R11)C(═O)N(R10)—, —N(R11)SO2N(R10)—, —N(R11)C(═S)N(R10)—, —N(R11)C(═O)—, —N(R11)SO2—,...

20060189597 - Lactam compounds and pharmaceutical use thereof: An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient....

20060189598 - Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method:

20060189599 - Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking: Certain atypical antipsychotic medications (particularly clozapine) or combinations of medications are useful to treat alcohol or other substance abuse, particularly in the general (non-schizophrenic) population. Generally stated, one aspect of the invention features a method of treating a patient suffering from alcohol or other substance abuse by administering to the...

20060189600 - Benodiazepine spirohydantoin cgrp receptor antagonists: The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the...

20060189601 - Antibacterial agents: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans....

20060189602 - Pyridazinone compounds: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus....

20060189603 - Nitric oxide enhancing diuretic compounds, compositions and methods of use: The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or...

20060189604 - Compounds: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man....

20060189607 - Long-acting betamimetics for the treatment of respiratory complaints: c

20060189606 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity....

20060189605 - New pharmaceutically-active compounds for the treatment of respiratory diseases: e

20060189609 - 1, 8-naphthyridine derivatives and their use to treat diabetes and related disorders: wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for...

20060189608 - Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors: The present invention provides compositions and methods for treating ocular neovascularization, angiogenesis, retinal edema, diabetic retinopathy, and/or retinal ischemia in order to prevent the loss of visual acuity associated with such conditions. More specifically, the present invention provides compositions containing receptor tyrosine kinase (RTK) inhibitors having unique binding profiles and...

20060189610 - Peripheral cannabinoid receptor (cb2) selective ligands: Novel polycyclic cannabinoid analogs are presented which have preferentially high affinities for the cannabinoid CB2 receptor sites....

20060189611 - Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors: Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV)...

20060189612 - Pharmaceutically active morpholinol: Disclosed is the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them, and processes for their preparation and use; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or...

20060189614 - Substituted diamino-1,3,5-triazine derivatives: the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R1 and R2 are each independently selected from hydrogen; hydroxy; amino; optionally substituted C1-6alkyl; C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; Ar1; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)-aminocarbonyl; dihydro-2(3H)-furanone; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido...

20060189613 - Sulphonamide compounds that modulate chemokine receptor activity (ccr4): The invention provides pyrimidine, pyridazine and triazine compounds for use in therapy....

20060189615 - 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders...

20060189616 - 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists....

20060189617 - Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists....

20060189619 - 3-({4-[2-(4-tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds: The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists....

20060189618 - 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists....

20060189620 - Immunosuppressive effects of pteridine derivatives: This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the...

20060189621 - Benzofuran derivative: each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the...

20060189622 - Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations: In the formula, A1, A2 and A3 are independent of each other and each represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a 5- to 14-membered non-aromatic heterocyclic group, a C6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may be substituted;...

20060189623 - Inhibitors of c-fms kinase: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast...

20060189624 - Novel combination for treating sexual dysfunction: Disclosed is a combination preparation for the treatment of sexual dysfunction in men or women containing at least one active ingredient A and one active ingredient B as pharmaceutically active ingredients, whereby the active ingredient A is a PDE inhibitor, preferably a cGMP PDE inhibitor and the active ingredient B...

20060189626 - Bi-pyridinyl derivatives as nk-1 antagonists: wherein R1 and R1′ are each independently hydrogen or methyl and X is —C(O)N(CH3)— or —N(CH3)C(O)—, and to pharmaceutically acceptable acid addition salts thereof for the treatment of numerous inflammatory conditions, migraine, rheumatoid arthritis, asthma, inflammatory bowel disease, mediation of the emetic reflex, Parkinson's disease, anxiety, depression, psychosis, motion sickness,...

20060189625 - Cyclic aminophenyl sulfamate derivative: wherein each of R1 and R2 stands for hydrogen or lower alkyl; each of R3 and R4 stands for hydrogen, halogen, cyano or the like; A stands for nitrogen or CH; B stands for CH2, SO2, CO, optionally substituted phenyl or the like; and R5 stands for alkyl, phenyl, amino...

20060189627 - Raf inhibitor compounds and methods: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed....

20060189628 - Compounds useful as chemokine receptor antagonists: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer, and osteolytic bone...

20060189629 - N-substituted benzimidazolyl c-kit inhibitors:

20060189630 - Mitotic kinesin inhibitors: The present invention relates to cycloalkylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals....

20060189631 - Substituted imidazopyrimidines for the prevention and treatment of cancer: Compounds of general formula (I), wherein from A1 to A5, and from B1 to B5 are H, alkyl, alkoxyl, halogen, carboxylic derivatives or sulfur derivatives, among others; and from P1 to P3 are H, halogen, alkyl or alkoxyl, among others. Said compounds may be used for the chemoprevention and treatment...

20060189633 - Preparation of amorphous form of indiplon: The present invention is directed to amorphous form of indiplon, to processes for preparing said amorphous form, to pharmaceutical compositions containing the same, and to method of treatment using the same. Additionally, the present invention also relates to the preparation of solid amorphous dispersion of indiplon and a carrier which...

20060189632 - Pyrazolo[1,5-a] pyrimidine derivatives: The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease,...

20060189634 - Fungicide mixtures: e

20060189635 - Enhanced efficacy benzisoxazole derivative dosage forms and methods: Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that provide enhanced efficacy when used in the treatment of schizophrenia and/or bipolar mania....

20060189636 - Inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia....

20060189637 - Anilinoquinazaolines as protein tyrosine kianse inhibitors: Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition....

20060189638 - 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds: Substituted 4-piperidin-1-yl-7H-pyrrolo[2,3-D]pyrimidine compounds are disclosed, as well as compositions comprising them and methods of their use for the treatment, prevention and management of various diseases and disorders....

20060189639 - Antagonists of the mglu receptor and uses thereof: b

20060189640 - Method of increasing drug oral bioavailability and compositions of less toxic orotate salts: The present invention relates generally to the method of increasing the oral bioavailability, reducing chemotherapy induced toxicity and side effects, and improving the effectiveness of pharmaceutical agents that are poorly absorbed from the gastrointestinal tract. Specifically, the invention relates to poorly absorbed pharmaceutical drugs and converting them to orotate salts....

20060189641 - Novel 6-phenlyphenanthridines: e

20060189643 - Novel heterocyclic compounds having anti-hbv activity: This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases....

20060189642 - Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases: The invention relates to the administration of roflumilast oral or intravenously and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases....

20060189644 - Lipid-modified immune response modifiers: Lipid-modified immune response modifier compounds, pharmaceutical compositions containing the compounds and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed....

20060189645 - Novel 6-phenylphenantridines: Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51, R6, R7 and R8 have the meanings indicated in the description, are novel effective PDE4 inhibitors....

20060189647 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof: wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized...

20060189646 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof: wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by...

20060189648 - Compositions useful for increasing lower esophageal sphincter pressure: The present invention relates to a method of increasing the pressure of the lower esophageal sphincter in a subject in need thereof comprising administering to said subject a specified amount of a compound having 5-HT3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The subject in...

20060189649 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R11 and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such...

20060189651 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma...

20060189650 - Novel piperidine derivatives as modulators of chemokine receptor ccr5: Compounds of formula (I) wherein R1, R2R3, R4, Λ, X, m and n are as defined; compositions comprising them, processes for preparing them and their use in medical therapy them and their use in medical therapy (for example mod ulating CCR5 receptor activity in a warm blooded animal)....

20060189652 - New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents: m

20060189654 - Novel compounds: This invention relates to cinnamate salts of 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one....

20060189653 - Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones: The invention relates to a process for preparing 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-ones. The process involves (i) reacting (a) 8-hydroxy-(1H)-quinolin-2-one with an acylating agent and a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one; or (b) 8-hydroxy-(1H)-quinolin-2-one with an acylating agent to form 8-acetoxy-(1H)-quinolin-2-one, and treating, in-situ, the 8-acetoxy-(1H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one;...

20060189655 - Methylphenidate derivatives and uses of them: e

20060189657 - Novel compounds and compositions as cathepsin inhibitors: Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making....

20060189656 - Piperidine derivatives and agent comprising the derivative as active ingredient: v

20060189658 - Substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals....

20060189660 - 5-(4-(2-n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl thiazolidine - 2,4-dione and pharmaceutical compositions comprising the same: A compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (‘Compound (I)’), or a pharmaceutically acceptable form thereof, in particulate form wherein the median value of the volume mean diameter of the particles is within the range 500 nm to 5 micrometres and medicinal uses thereof....

20060189659 - Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt: (ii) provides an infra red spectrum containing peaks at 764 and 579 cm−1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such...

20060189661 - Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists: The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed....

20060189662 - Novel liquid preparation: It is an object of the present invention to provide a liquid preparation which excels in stability with no occurrence of precipitates and lees even after long storage. The liquid preparation contains a lipophilic material, a sucrose fatty acid ester, a polyoxyethylene hydrogenated castor oil, a polyglycerin fatty acid ester,...

20060189663 - Pyrrole-2,5-dithione derivatives as liver x receptor modulators: to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance,...

20060189664 - Diphenylpyridine derivatives, preparation and therapeutic application thereof: or R1 and R2, together with the nitrogen atom to which the above are bonded, form a 4-disubstituted piperidin-1-yl group; the salts, solvates and hydrates thereof. The invention further relates to a method for production and therapeutic application thereof....

20060189665 - Oxamide derivatives useful as raf-kinase inhibitors: The present invention relates to oxamide derivatives of Formula (I), the use of the compounds of Formula (I) as inhibitors of raf-kinase, the use of the compounds of Formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient....

20060189666 - Novel gamma-secretase inhibitors: Compounds of Formula (I): inhibit the processing of APP by gamma-secretase, and hence are useful for treatment or prevention of Alzheimer's disease....

20060189667 - Ppar-activating compound and pharmaceutical composition comprising the compound: (wherein each of R1 and R2, which may be identical to or different from each other, represents a hydrogen atom, a methyl group, or an ethyl group; each of R3a, R3b, R4a, and R4b, which may be identical to or different from each other, represents a hydrogen atom, a halogen...

20060189668 - Method of treating hyperproliferative disorders using heterocyclic inhibitors of mek: or a solvate or pharmaceutically acceptable salt thereof, wherein R1, R2, R7, R8, R9, R10, W and Y are as defined in the specification. Also disclosed are methods of treating hyperproliferative diseases, such as cancer and inflammation, in mammals, said method comprising administering to a mammal an effective amount of...

20060189669 - Pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy: To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof....

20060189670 - Process for the preparation of anastrozole and intermediates thereof:

20060189671 - Compounds, compositions, and methods: 1,2,4-Tiazole-5-ones useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed....

20060189672 - Viral polymerase inhibitors: 2

20060189673 - Phenylazole compound, production process therefor and antioxidant: (wherein R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or the like, k represents 0 or an integer of 1 to 15, and R5 and R6 may be identical or different from...

20060189674 - Deacetylase inhibitors: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties....

20060189675 - Crystalline form of a drug: Atrasentan Hydrochloride Crystalline Form 1, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed....

20060189676 - Pyrrolcarboxamides and pyrrolcarbothioamides: r

20060189677 - Ion channel modulating compounds and uses thereof: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local...

20060189678 - 4,5-dihydronaphtho[1,2-b]thiophene derivative: (wherein R1 is a C1 to C10 1-hydroxyalkyl group or a C1 to C10 acyl group, and R2 and R3 separately substitute in the 6-, 7-, 8-, or 9-positions, and are each independently a hydrogen atom, a halogen atom, a C1 to C10 alkyl group, a hydroxy group, a C1...

20060189679 - C10 cyclopropyl ester substituted taxane compositions: Compositions comprising a taxane having a cyclopropyl ester substituent at C10, a keto substituent at C9, a hydroxy substituent at C7, a 2-furyl substituent at C3′ and an isobutoxycarbamate substituent at C3′....

20060189680 - Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents: Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation...

20060189681 - Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same: and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain...

20060189682 - Water soluble prodrugs of cox-2 inhibitors: Disclosed are water soluble compounds which are useful as prodrugs of COX-2 inhibitors, and pharmaceutical compositions comprising them....

20060189683 - Parenteral formulation of mycophenolic acid, a salt or prodrug thereof: A pharmaceutical composition in the form of powder or a lyophilized composition for injection suitable for parenteral administration comprising MPA, a salt or a produg thereof....

20060189684 - 3-phenylfuran-2-one derivatives as cox-2 inhibitor: The present invention relates to 3-phenylfuran-2-ones of formula (I), processes for their preparation, pharmaceutical compositions containing them, and their medical uses....

20060189685 - Formulations of ladostigil tartrate: Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof....

20060189686 - Use of a combination of substances to prevent biofouling organisms: This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods....

20060189687 - S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have...

20060189688 - Use of sodium 2-mercaptoethanesulfonate as antiviral agent: The use of the sodium 2-mercaptoethanesulfonate (MESNA) as antiviral agent, particularly as an anti-influenza agent....

20060189689 - Arginine mimetics as factor xa inhibitors: The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor Xa; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic therapy....

20060189690 - Compounds to affect insect behavior and/or bird behavior: Various exemplary compounds, compositions, methods and devices are disclosed. An exemplary composition or formulation includes methyl anthranilate, fatty acid and an amine such as, but not limited to, monoethanolamine or triethanolamine. Such an exemplary composition is optionally an emulsion. An exemplary method applies an exemplary compound to an insect nest....

20060189692 - Novel anti-proliferative pharmaceutical composition: The use of urocanic acid or another pharmaceutically acceptable agent being able to acidify the cell cytoplasm for the manufacture of a pharmaceutical composition useful for causing inhibition or halting of transformed or non-transformed cell proliferation in a person or an animal, where an effective amount of the agent is...

20060189691 - Use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person: The use of urocanic acid or another pharmaceutically acceptable agent being able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing inhibition or halting of transformed or non-transformed cell proliferation in a person or an animal, where an effective amount of the agent is...

20060189694 - Composition and method for treating neurological disease: The invention provides methods and compositions for treating or preventing neurological disorders....

20060189693 - Methods of treatment with lxr agonists: The present invention relates generally to the use of LXR agonists in the prevention and/or treatment of cardiovascular pathology....

20060189695 - External preparation for improving coital function: The present invention provides a preventive or a remedy for penile erectile dysfunction, which promotes blood-flow in a penile sponge body over long time and thus induces erection while showing high safety without any adverse effect on a body as a whole, when externally administered to a penis. Use of...

20060189697 - Crystalline acat inhibitor: The invention is directed to the Form A polymorph of N-benzyl-N′-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide and its use as a therapeutic/cosmetic agent....

20060189696 - Polyamine conjugates with acidic retinoids and preparation thereof: Invented are novel polyamine conjugates which have been readily obtained using as key-step the condensation of linear, conformationally restricted, cyclic and branched polyamides or suitably protected derivatives with vitamin A derivatives. These compounds inhibit the ribozyme rivbonuclease P (RNase P) and the production of interleukin-2 (IL-2) amd interferon-γ (INF-γ) by...

20060189698 - Treatment of interstitial cystitis: The present invention relates to compositions and methods of alleviating a symptom of chronic pelvic pain syndrome with an amphetamine. Specifically, the invention includes a method of administering dextroamphetamine or a salt thereof to an animal in order to treat interstitial cystitis, vulvovaginits and/or vulvodynia. The invention also includes a...

20060189699 - Antimicrobial trinervitane derivatives: The present invention relates to a novel class of antimicrobial compounds. These trinervitane compounds can be used for a variety of purposes such as for the treatment of microbial infections and diseases, and as disinfectant agents....

20060189700 - Pharmaceutical compositions: Pharmaceutical compositions containing 2,6-diisopropylphenol (propofol) are described for use as. anaesthetics. A method for their preparation is described, as their use in producing anaesthesia including induction and maintenance of general anaesthesia and sedation....

20060189701 - Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections: A method for killing infectious microbial cells by exposing the microbial cells to endogenous antimicrobial compounds. Activation of the antimicrobials is achieved by addition of low permeability, non-ionic osmolytes to lower ionic strength in body fluids where the antimicrobials have been previously suppressed by alteration of ionic transport (increase in...

20060183665 - Modulators of the potassium channels twik-1, task-1 gorl1. sk2 pr pcn1, used to treat arrhythmia, coronary heat disease or hypertension: The invention relates to the use of modulators of the potassium channels TWIK-1, TASK-1, GIRK1 SK2 and PCN1 for producing a medicament for the treatment and/or prophylaxis of cardiac dysrhythmias (arrhythmias), coronary heart disease, and hypertension....

20060183664 - Pharmaceutical composition for delayed hypersensitivity: The present invention provides a pharmaceutical composition by a novel action mechanism without serious side effects for delayed hypersensitivity and a screening method of the same. The invention also provides a novel assay method of inhibitors/suppressive agents of PAR-2. The invention relates to a pharmaceutical composition for delayed hypersensitivity containing...

20060183670 - Autoantigen composition: The invention features methods for the prevention or treatment of autoimmune disorders in humans. The methods include administering an autoantigen in combination with an oil-based carrier. Included are methods for the prevention and treatment of diabetes mellitus which include treating a patient with a diabetes type 1 autoantigen, e.g., human...

20060183666 - Method of purifying preproinsulin: The invention relates to a method for the chromatographic purification of preproinsulins, in which higher molecular weight substances are removed from an aqueous solution of preproinsulin by a first chromatography on an anion exchanger in flow-through mode and a subsequent second chromatography on a cation exchanger in adsorption mode, and...

20060183668 - Novel insulin derivatives: e

20060183669 - Separation of polypeptides comprising a racemized amino acid: Method for purifying a racemized polypeptide by ion-exchange chromatography....

20060183667 - Stabilised insulin compositions: The present invention relates to human insulin analogues having a fast onset of action. These analogues may have amino acid in position B26 substituted with Phe, or be Des(B30) analogues of human insulin. The invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of...

20060183671 - Treatment of anemia: The present invention relates to a method for the treatment of anemia based on the administration of the product of growth arrest-specific gene 6 (Gas6), its mutants, variants, active derivatives and the physiological tolerated salts of said Gas6 derivatives or of a group of biologically active substances inducing a GAS6...

20060183672 - Glycoprotein hormone superagonists: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where...

20060183673 - Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof: e

20060183674 - Compositions and methods for treating diabetes: Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided....

20060183675 - Antimicrobial polypeptide from aspergillus niger: The present invention relates to an anti-microbial polypeptide and a DNA construct encoding said anti-microbial polypeptide and the use of said anti-microbial polypeptide....

20060183683 - Liquid composition of factor vii polypeptides: The invention concerns a liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 9.0; (iii) an agent selected from the group consisting of: a calcium salt, a magnesium salt, or a mixture thereof; wherein...

20060183678 - Nogo a binding molecules and pharmaceutical use thereof: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant <1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising...

20060183677 - Novel exendin agonist formulations and methods of administration thereof: Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake....

20060183686 - Novel nucleic acid molecules and polypeptides encoding baboon tafi: The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and...

20060183687 - Novel therapeutic molecules: The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as “Bim”, and to genetic sequences encoding same....

20060183685 - Peptide pharmaceutical formulations: A pharmaceutical composition for administration to a mammal is disclosed. The composition includes a therapeutically effective amount of a peptide, such as a GLP-1 molecule, a PTH molecule, or a GRF molecule. The composition further includes a buffer including a weak acid having an acid dissociation constant value of greater...

20060183679 - Peptides having a high cysteine content: The invention relates to cysteine containing peptides of the structure XXCCXXXXXXXCXXXCXXXXXXQXXCXXXCXCXXXXXXXCXXXXXX, of the structure XXCCXXXXXXXCXXXCXXXXXXXXXCXXXCXCXXXXTXXCXXXXXX and of the structure XXCCXXXXXXXCXXXCXXXXXXXXXXCXXXCXCXXXXXXXXCXXXXXX, wherein X, independently of one another, represents any naturally occurring amino acid, as well as to nucleic acid sequences encoding said peptides, to vectors comprising said sequences, as well as...

20060183680 - Remedy for ischemia: The present invention provides a ischemia therapeutic agent that contains vascularization induction factor and gelatin hydrogel, and gradually releases vascularization induction factor, which is useful in treating ishchemia accompanying peripheral circulatory disorders etc. encountering as complications of arteriosclerosis obliterans, Buerger's disease, diabetes and collagen disease....

20060183681 - Stabilized compositions containing natriuretic peptides: Stabilized compositions of natriuretic peptides comprise the peptide and an effective stabilizing amount of (i) an alkyl or aryl sulfonyl fluoride protease inhibitor, or (ii) benzamidine:...

20060183682 - Stabilized pharmaceutical peptide compositions: Method for increasing the shelf-life of a pharmaceutical composition comprising a glucagon-like peptide which is prepared from a peptide product that has been dried at a pH above neutral pH....

20060183684 - Therapeutic combination of a vegf antagonist and anti-hypertensive agent: Disclosed are compositions and methods for treating a disease or condition related to angiogenesis with a vascular endothelial growth factor (VEGF) inhibitor and one or more anti-hypertensive agent(s). The method of the invention is useful for preventing the development of hypertension and/or reducing hypertension in a subject treated with a...

20060183676 - Treatment of mycobacterium tuberculosis with antisense oligonucleotides: Methods of inhibiting the proliferation of Mycobacterium tuberculosis comprising contacting Mycobacterium tuberculosis with an effective amount of a polynucleotide complementary to an mRNA transcript expressed by Mycobacterium tuberculosis are provided. Typical methods of the invention utilize phosphorothioate modified antisense polynucleotides (PS-ODNs) against the mRNA of M. tuberculosis genes such as...

20060183688 - Peptide interacting with anti-apoptotic proteins of the bcl-2 family: The invention relates to the identification of a new peptide interacting with the anti-apoptotic proteins Bcl-2, Bcl-W and/or Bcl-XL, and also to screening methods allowing identification of modifiers of those interactions....

20060183689 - Activation of peptide prodrugs by hk2: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods...

20060183690 - Anti-hypertensive dietary supplement: An anti-hypertensive fish protein hydrolysate is provided, wherein the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein hydrolysate comprises at least 1 peptide selected from the group consisting of: Leu-Ala-Phe, Leu-Thr-Phe, Ile-Ile-Phe, Leu-Ala-Tyr, Ile-Ala-Tyr, Val-Phe-Tyr, Tyr-Ala-Tyr, Val-Leu-Trp, Ile-Ala-Trp, Tyr-Ala-Leu and Tyr-Asn-Arg. Methods of making and...

20060183691 - Anti-hypertensive molecules and process for preparation thereof: The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention particularly relates to the preparation of novel Angiotensin Converting Enzyme Inhibitors (ACEI) with prolonged activity. ACE inhibitors play an important role in Renin-Angiotensin-Aldosteron system (RAAS)...

20060183694 - Hepatitis c virus inhibitors: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease....

20060183695 - Methods of increasing endogenous erythropoietin (epo): The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds....

20060183693 - Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine: A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a...

20060183692 - Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy: According to the invention there is provided a cholesterol lowering therapy method and a method for modification of lipid (triglyceride), lipoprotein, and apolipoprotein profiles associated with an increased risk of cardiovascular complications comprising the administration of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, to a...

20060183696 - Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract: wherein M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, T represents an anti-inflammatory subunit that can be a steroid or nonsteroid (nonsteroidal moiety) derived from a non-steroid drug with anti-inflammatory, analgesic and/or antipyretic activity (NSAID) and L represents a linker covalently linking M and T....

20060183697 - Complexing of medicinal substances with high-molecular carriers and injection and infusion solutions containing said complexes: A molecular complex of a high molecular weight carrier substance and of a medicinal substance. The carrier substance has functional groups whereby the carrier substance and the medicinal substance are bound non-covalently. The medicinal substance is insoluble or slightly soluble in water and the carrier substance is readily soluble in...

20060183698 - Ophthalmic formulations and uses thereof: Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation...

20060183699 - Vaccines containing ribavirin and methods of use thereof: Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating...

20060183702 - Aptamers to von willebrand factor and their use as thrombotic disease therapeutics: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further...

20060183700 - Cgrp binding nucleic acids: The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide....

20060183703 - Circular expression construct for gene therapeutic applications: Method for producing a circular minimalist expression construct closed in an annular manner, from a double-strand DNA, an expression construct produced according to said method, and the use of the same in gene therapy and vaccination. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b)....

20060183705 - Hepatitis c virus codon optimized non-structural ns3/4a fusion gene: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions...

20060183704 - Method to inhibit cell growth using oligonucleotides: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising pTT or a composition comprising one or more oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment...

20060183701 - Methods and compositions for determining non-specific cytotoxicity of a transfection agent: Methods and compositions for determining cytotoxicity of a transfection agent are provided. In one aspect, a cell is contacted with a transfection agent. Following contact, a cytotoxic marker profile of the cell is evaluated to determine whether the transfection agent has mediated a cytotoxic response in the cell. Also provided...

20060183706 - 2-beta-modified-6-substituted adenosine analogs and their use as antiviral agents: Various 2′-beta-methyl-6-substituted adenosine analogs (including 2,6-disubstituted adenosine, 8-aza-6-substituted adenosine, and 2-aza-6-substituted adenosine) are prepared by conventional and combinatorial library approaches. Contemplated compounds are particularly useful as therapeutic agents, and especially as antiviral agents....

20060183707 - Production method of 2'-deoxyguanosine compound: r

20060183708 - Topical delivery of trace metals for enzyme modulation: The present invention relates to a method for topical delivery of trace metals for the modulation of certain metalloenzymes. The method of topical delivery of the present invention comprises; (i) mixing of a trace metal salt of a phosphorylated nitrogen heterocyclic base complexed with a chelating agent [FIG. 1], and...

20060183710 - Chlamydia oligosaccharides: Oligosaccharides specific for Chlamydia mediate attachment of the organism to host cells....

20060183709 - Preparation of low molecular weight hyaluronic acid as a food supplement: A process for preparing hyaluronic acid primarily as a food supplement which is capable of absorption and assimilation by the human body includes desirable control of both the purity and molecular weight range of the resulting product. Chicken comb tissue is subjected to one of two disclosed processes for extracting,...

20060183711 - Method and composition for treatment of a mucosal tissue disorder: Methods of treating a subject suffering from a disorder in a mucosal tissue, such as interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease; inflammatory bowel disease or colitis, by administering a medicament containing a sulfated chitinous polymer administered topically are described. Pharmaceutical compositions...

20060183712 - Affinity purified heparin/heparan sulfate for controlling the biological activity of the fgf receptor: Methods and compositions for modulating the activity of a FGF receptor in a mammal are disclosed. The methods and compositions utilize substantially purified heparin/heparan sulfate oligosaccharides (HS) that have high affinity for FGF7. HS that has high affinity for FGF7 has increased activity for promoting the formation of a ternary...

20060183713 - Compositions of low molecular weight heparin produced with modified heparinase iii: The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention....

20060183714 - 3-alpha-glycosyl alpha, alpha-trehalose compound, process for producing the same, and use: e

20060183715 - Sulfated fucoglucuronomannan: An enzyme which decomposes a sulfated fucoglucuronomannan and is useful in the field of glycotechnology; a process for producing the enzyme; a fucoidan fraction reduced in the number of the kinds of molecules and useful as a reagent in glycotechnology; a sulfated fucoglucuronomannan oligosaccharide; and processes for producing the fraction...

20060183716 - 2-methylene-19-nor-(20s-24s)-1alpha,25-dihydroxyvitamin d2: Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions....

20060183717 - Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative: m

20060183718 - Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,...

20060183720 - 9-substituted tetracyclines: s

20060183719 - Tetracycline metal complex in a solid dosage form:

20060183721 - 2-methylene-19-nor-(20s-24epi)-1alpha,25-dihydroxyvitamin d2: Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions....

20060183722 - Formulation for lipophilic agents: The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same....

20060183723 - Ethercarboxylic acid ester of sterol or stanol: The disclosed invention relates to sterol and/or stanol esters of ethercarboxylic acids corresponding to general formula (I):R(OAlk)nOCH2COOH, in which R is a C1-50 alkyl, alkenyl and/or alkylphenyl group derived from an alcohol, OAlk stands for ring-opened ethylene oxide, propylene oxide and/or butylene oxide units and n is a number of...

20060183724 - Compositions of unconjugated estrogens and methods for their use: The present invention relates to compositions containing unconjugated estrogens and methods of their use in the treatment of conditions associated with hypoestrogenism or reduced estrogen levels in females....

20060183725 - Pharmaceutical preparation for oral contraception: The pharmaceutical preparation for oral contraception has 28 daily dosage units, of which at least 21 daily dosage units each contain from 1.5 mg to 2 mg of dienogest and from 0.015 mg to 0.02 mg of ethinyl estradiol together in a pharmaceutically acceptable carrier. Seven or fewer daily dosage...

20060183726 - Pharmaceutical compositions based on anticholinergics and etiprednol: The present invention relates to novel pharmaceutical compositions based on anticholinergics and etiprednol, processes for preparing them and their use in the treatment of respiratory diseases....

20060183727 - Estrogenic compounds as anti-mitotic agents: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods....

20060183728 - Combination chemotherapy compositions and methods: This invention relates to combination therapies involving anticancer chemotherapeutic agents and isoflavones or analogues thereof. The invention further relates to compounds, compositions, methods and therapeutic uses involving, containing, comprising, including and/or for preparing platinum-isoflavonoid complexes suitable for use in the combination therapies of the invention....

20060183729 - Vanadium compounds as anti-angiogenic agents: Vanadium compounds for inhibiting angiogenesis useful for treating or preventing diabetic retinopathy, hemangiomas, cancers with abnormal blood vessel supply, restenosis following vascular injury, and the like....

20060183730 - Novel carbapenem compounds: n

20060183731 - 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity: The present invention is directed to compounds of the formula: wherein R1, R1, R3, R4, R5, R6, R7, R8, R9, R10 and R16 are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2....

20060183732 - Novel lactams and uses thereof: This invention relates to novel compounds having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein. The present invention relates to...

20060183733 - Treating microvasculature diseases with acetyl cholinesterase inhibitors: There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune/inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal...

20060183734 - Cyclohexylphenyl vasopressin agonists: wherein Y is NR or —(CH2)n; R is H or alkyl; “Z” represents optionally substituted phenyl or a 6-membered aromatic ring having one nitrogen atom; “W” represents a optionally substituted phenyl or 5-membered aromatic ring having one nitrogen atom; “X” represents an optionally substituted 5-membered aromatic ring having one sulfur...

20060183735 - Methods for identifying compounds for regulating muscle mass or function using dopamine receptors: Screening methods for identifying compounds that bind to or activate (D1 or D5 dopamine receptors individually or in combination) or regulate or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of D1 or D5 dopamine...

20060183736 - Selective estrogen receptor modulators containing a phenylsulfonyl group: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata....

20060183737 - Treatment of t-helper cell type 2-mediated immune diseases by retinoid antagonists: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases....

20060183738 - Crystalline forms of nevirapine: The present invention relates to novel crystalline forms of 11-cyclopropyl-5, 11-dihydro-4-methyl-6H-dipyrido[3,2-b: 2′, 3′-e][1,4]diazepin-6-one, generically kiown as Nevirapine, and processes for making thereof. More specifically, the present invention provides novel crystalline Forrn-II and Form-III of Nevirapine....

20060183739 - Carbonyl compounds: Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours....

20060183740 - Novel salt form of a dopamine agonist: v

20060183741 - Novel substituted diamine derivatives useful as motilin antagonists: wherein R1, R2, R3, R4, X1, X2, X3, X4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such...

20060183742 - Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses: Novel compounds of the formula (I), in which R, R1, R2 and R3 have the meanings indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours....

20060183743 - Kappa opioid receptor ligands: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions....

20060183744 - Method for treating depression and/or anxiety: This invention relates to the treatment and/or prevention of depression and/or anxiety disorders and/or dementia by the administration of an estrogen receptor beta (ERβ) selective agonist either as a single agent, or in combination with other agents....

20060183745 - Vanilloid receptor ligands and their use in treatments: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic...

20060183746 - Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds: and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, may in certain embodiments be used to treat patients suffering from one or more diseases responsive to inhibition of tyrosine kinase activity. The diseases may, for instance, be responsive to inhibition of Btk activity and/or B-cell...

20060183747 - Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors: X2 represents a direct bond; —NR1—; —NR1—(CH2)n3—; —O—; —O—(CH2)n3—; —C(═O)—; —C(═O)—(CH2)n3—; —C(═O)—NR5—(CH2)n3—; —C(═S)—; —S—; —S(═O)n1—; —(CH2)n3—; —(CH2)n4—X1a—X1b—; —X1a—X1b—(CH2)n4—; —S(═O)n1—NR5—(CH2)n3—NR5— or —S(═O)n1—NR5—(CH2)n3—; R3 represents an optionally substituted 5- or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, or a 9- or 10-membered bicyclic heterocycle containing...

20060183748 - Identification of compounds that inhibit replication of human immunodeficiency virus: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum....

20060183749 - Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis: The present invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having anti-proliferative and antiangiogenic activities, as well as methods for treating various diseases associated with abnormal cell proliferation, including cancer, or associated with unregulated angiogenesis including growth and metastasis of solid tumors,...

20060183750 - Treatment of metastasized tumors: Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt...

20060183751 - Pyrazole compounds: Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount....

20060183752 - Process for preparing 2, 3-disubstituted indoles: a) reacting a bromoindole compound (i) with a dialkoxyl C1-5 borane in the presence of a ligand, a palladium catalyst and a base to make a compound of general formula (ii); or alternatively reacting compound (i) with a trialkyl magnesiate reagent, followed by treatment with a borate; b) reacting the...

20060183754 - Amide bridged piphenyl or biazaphenyl derivatives: and R1 to R13, X1, X2, m and n are defined in the description, and all pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which...

20060183753 - Use of substituted 2,5-diamidoindoles for the treatment of urological diseases: The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.RCK 41-Foreign Countries...

20060183756 - Pyrrazolo-pyrimidine derivatives: e

20060183755 - Tyrosine kinase inhibitors: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory...

20060183757 - Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier: The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling, such as by using fluphenazine, can be used to modulate the immune response, cell proliferation, and apoptosis, among other cell...

20060183758 - Method for synthesis of aza-annelated pyrroles, thiophenes, and furans: Methods of synthesis of intermediates that are useful as bioisosteres of the indole, benzofuran and benzothiophene scaffold are disclosed....

20060183759 - Tissue transglutaminase inhibitors: The present invention provides novel compounds and methods useful for treating transglutaminase associated disorders such as celiac spru, Alzheimer's disease and Huntington's disease. Certain compounds of the invention are tissue transglutaminase inhibitors that comprise thiophene moieties. Methods of the invention include treatment of transglutaminase associated disorders with inhibitors of transglutaminase....

20060183760 - New purine derivatives: R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke,...

20060183761 - Pyrrolopyrimidines useful as inhibitors of protein kinase: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders....

20060183762 - 3-aminoquinazolin-2,4-dione antibacterial agents: Antibacterial 3-aminoquinazolin-2,4-diones have formula (I) wherein: R1 and R3 include alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl; R5, R6, and R8 include H, alkyl, alkoxy, halo, NO2, CN, NH2, alkyl and dialkylamino; R7 includes hydrogen, alkyl, cycloalkyl, heterocyclic, fused heterocyclic, aryl and fused aryl; J and K are C...

20060183763 - Novel pyrrolidyl derivatives of heteroaromatic compounds: The invention pertains to new pyrrolidyl derivatives of benzo-fused aza heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use...

20060183764 - Combination of gh secret agogues and pde4 inhibitors for the treatment of alzheimers disease: There is disclosed the treatment or prevention of diseases involving deposition of beta-amyloid in the brain, e.g. Alzheimer's disease, via the combined administration of a growth hormone secretagogue and a PDE4 inhibitor....

20060183765 - Methods of treating cancer using an fpt inhibitor and antineoplastic agents: Disclosed is a method of treating cancer in a patient in need of such treatment comprising administering a therapeutically effective amount of an FPT inhibitor and therapeutically effective amounts of one or more antineoplastic agents. Methods of treating non small cell lung cancer, CML, AML, non-Hodgkin's lymphoma and multiple myeloma...

20060183766 - Orally bioavailable cci-779 formulations: A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66±about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7±9.6 ng/mL and an...

20060183767 - Methods of stimulating immune response in certain individuals: Methods to stimulate host immune system against viral infections are disclosed. Methods to stimulate immune response of a virally, influenza or cancer infected individual through an immunomodifier such as a non-nucleoside imidazoquinolinamine (heterocyclic amine) are disclosed....

20060183768 - Compounds: L is (CH2)n, where n is 0, 1, 2, 3 or 4; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; the products of mono- and di-oxidation of sulphur and/or mono-oxidation of nitrogen moieties in compounds of formula I; or a pharmaceutically acceptable salt thereof. These compounds find...

20060183769 - Benzoxazole carboxamides for treating cinv and ibs-d: i

20060183770 - Sulfonamide derivative having isoxazole ring:

20060183771 - Novel combination of selective factor viia and/or factor xia inhibitors and selective plasma kallikrein inhibitors: The present invention relates to a novel pharmaceutical combination for treating thromboembolic and/or inflammatory diseases, wherein the combination has: (a) a first therapeutic agent independently selected from the group consisting of a selective Factor VIIa inhibitor, a selective Factor XIa inhibitor, a combination of the selective Factor VIIa and XIa...

20060183772 - Anti-cancer compounds: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers....

20060183774 - Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including...

20060183773 - Uses of methylphenidate derivatives:

20060183775 - Use of indazole derivatives for the treatment of neuropathic pain: Use of a compound of formula (I), wherein X is CH or N, and when X is CH, R is H, OH, a linear or branched alkyl chain having from 1 to 3 carbon atoms, a linear or branched alkoxy chain having from 1 to 3 carbon atoms, or a...

20060183776 - Liquid dosage formulations of donepezil: The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome,...

20060183777 - Process for halomethyl ethers of hydroxyiminomethyl quaternary pyridinium salts: A halide salt of a 1-(hydroxyiminomethyl-1-pyridino)-3-(halomethyl)-2-oxapropane is prepared by adding a pyridinealdoxime to a bis-halomethylether in such a manner that the bis-halomethylether is maintained in excess throughout the addition. This procedure produces the halide salt of a 1-(hydroxyiminomethyl-1-pyridino)-3-(halomethyl)-2-oxapropane in high yield and purity, which facilitates its use as an intermediate...

20060183779 - Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof....

20060183778 - Osteogenesis-promotion enhancer and method of screening the same: It is an object of the present invention to provide an excellent enhancer for an osteogenesis accelerator that can enhance the activity of BMP as an osteogenesis accelerator. Another object of the present invention is to provide a method of screening for a novel enhancer for an osteogenesis accelerator. The...

20060183780 - Pyrazole compounds useful in the treatment of inflammation: There is provided a compound of formula (I), wherein R1, R2, R3, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and...

20060183781 - Novel thiazolylmethyl pyrazoles, method for the production thereof, and use thereof in dyes for keratin fibers: wherein R denotes a straight-chain or branched C1-C6-alkyl group, an unsubstituted phenyl group or a singly or multiply substituted phenyl group wherein the substituents are selected independently of each other from among a halogen atom, a C1-C6 carboxylate ester group, a straight-chain or branched C1-C6-alkoxy group, a straight-chain or branched...

20060183782 - Methods of using thiazolidine derivatives to treat cancer or inflammation: Methods of using thiazolidine derivatives of formula (I) to treat cancer, inflammation, or other disorders related to the activities of protein phosphatases PTPN12 or PTPN2 in a mammal are disclosed. Pharmaceutical compositions containing such derivatives are disclosed....

20060183783 - Aryl carbonyl derivatives as therapeutic agents: This invention relates to aryl carbonyl derivativeswhich are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial....

20060183784 - Human growth hormone antagonists: i

20060183785 - Biaryl substituted pyrazoles as sodium channel blockers: Biaryl substituted pyrazole compounds are sodium channel blockers useful for the treatment of pain and other conditions. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treatment of conditions, including...

20060183786 - Injectable long-acting analgesic composition comprising an ester derivative of ketorolac:  R is a straight-chain or branched saturated or unsaturated C1-C20 aliphatic group optionally substituted with a C6-C10 aryl group; and (b) a pharmaceutically acceptable oil vehicle. The composition can provide a longer duration of action and, therefore, is suitable for use in the treatment of long-lasting pains and inflammations....

20060183787 - Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed....

20060183788 - Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of treating, managing or preventing exercise-induced asthma are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed....

20060183789 - Methods for preventing and treating obesity in patients with mc4 receptor mutations: Methods are provided for treating health conditions associated with altered MC4 receptor activity with melanin concentrating hormone receptor antagonists. Such compounds may be used, for example, to treat or prevent obesity and/or overeating, and to reduce body mass index, in patients carrying one or more MC4 receptor mutations....

20060183790 - Azolylacylguanidines as beta-secretase inhibitors: t

20060183791 - Substituted p-diaminobenzene derivatives: The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use....

20060183792 - Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators: e

20060183793 - Method of treating hematologic tumors and cancers: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1...

20060183794 - Drug composition containing nf-kb inhibitor: l

20060183795 - Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain: wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl...

20060183796 - Method for the medicinal prophylaxis of cholinesterase inhibitor intoxication, and active substances and medicaments suitable therefor: (S)-N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate (formula (1)) or at least one active ingredient according to formula (2) for the preventive protection of people from poisoning caused by cholinesterase inhibitors....

20060183797 - Fatty alcohols and fatty acid esters useful for treatment of inflammation: Immunomodulators selected from: (a) a saturated or cis-unsaturated C10-C20 fatty alcohol or an ester thereof with a C1-C6 alkanoic acid; (b) a monoester of a C2-C8 alkanediol or of Glycerol with a saturated or cis-unsaturated C10-C20 fatty acid; and (c) a diester of glycerol with a saturated or cis-unsaturated C10-C20...

20060183798 - Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent: A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said...

20060183799 - Biologically active oils: A process for the production of fats or oils and their extracts containing biologically-active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes b) incubating the inoculated substrate for a period of between about 7-120 days at a temperature...

20060183800 - Methods and fluorinated compositions for treating amyloid-related diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing amyloid-related disease....

20060183801 - Method of preventing or treating breast, prostate and/or cervical cancer with n, n-dimethylglycine: The invention relates to a method of treating, inhibiting the metastasis of, or preventing cervical, breast or prostate cancer comprising administering to a patient an effective amount of N,N-dimethylglycine or a pharmaceutically acceptable salt thereof....

20060183802 - Compositions and methods for treating amyotrophic lateral sclerosis (als): The present invention provides compositions and methods for treating ALS and other diseases, particularly motor neuron diseases that are mediated by aberrant aggregation of SOD. Patients with ALS may be treated using a compound of the invention which inhibits SOD aggregation mediated by a Cys-111 residue of SOD, or inhibits...

20060183803 - L-aspartic acid for the treatment of assorted health problems: A method of treating or preventing one's health problem that are associated with one's cells having a poor metabolic capability to process fat includes ingesting a therapeutically effective dosage of an anaplerotic precursor. Examples of such health problems include obesity and the related health conditions that are aggravated by obesity,...

20060183804 - Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions: Novel packaging, methods of packaging and methods for storing thyroid hormone pharmaceutical compositions, such as levothyroxine (T4) sodium and liothyronine (T3) sodium, in reduced oxygen conditions for maintaining the stability and potency of the thyroid hormones during extended shelf life are provided....

20060183805 - Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof: The subject invention provides therapeutically useful and therapeutically effective compounds and compositions for the treatment of a variety of disorders. The compounds of the invention exhibit significantly reduced levels of drug-drug interactions (DDI) and are metabolized, primarily, via non-oxidative systems....

20060183806 - Compositions and methods comprising long-chain, straight-chain 2-amino-3- hydroxyalkanes: Investigation of the activity of extracts of the clam Spisula polynyma has led to antitumour long-chain, straight-chain alkane or alkene compounds which have a 2-amino group and a 3-hydroxy group....

20060178293 - Cardiotonic polypeptides: A polypeptide which has a positive inotropic effect on cultured cardiomyocytes and is non-toxic to mammals. The polypeptide may be isolated from Buthinae scorpion venom. Also disclosed is a pharmaceutical composition comprising the polypeptide and a DNA molecule encoding the polypeptide....

20060178294 - Cell permeabilization and stabilization reagent and method of use: A cell permeabilization and stabilization reagent and method of use are disclosed. The reagent contains a N-acyl sarcosine or a salt thereof, a pH adjusting agent to adjust pH of the reagent in a range from about 4 to about 6; and an aqueous medium; the reagent having a low...

20060178292 - Methods and compositions of ecdysozoan molt inhibition: In general, this invention relates to nucleic acid and amino acid sequences involved in molting and the use of these sequences as targets for the development of compounds that disrupt Ecdysozoan molting, and are useful as insecticides, nematicides, and anti-parasitic agents....

20060178295 - Steroid conjugates, preparation thereof and the use thereof: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and hematological malignancies. Further the conjugates exhibit a synergistic action together with a cytoskeleton-acting drug such as Taxol®, which enable the treatment of cancers...

20060178296 - Night-time oral insulin therapy: A method for protection of a mammal that has impaired glucose tolerance or early stage diabetes mellitus from developing overt or insulin dependent diabetes comprises administering an orally effective dose of a pharmaceutical formulation comprising insulin at nighttime, e.g., at or shortly before bedtime....

20060178297 - Systems and methods for silencing expression of a gene in a cell and uses thereof: The present invention provides RNA-based systems that are capable of silencing expression of a gene in a cell. Also provided are pharmaceutical compositions, cells, and kits that include the systems; cultures of primary cells that have been contacted with the systems; use of the systems in methods of studying protein...

20060178298 - Antitumoral treatments: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies....

20060178301 - Albumin-fused ciliary neurotrophic factor: The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof....

20060178302 - Amyloid beta protein (globular assembly and uses thereof): The invention provides amyloid beta-derived dementing ligands (ADDLs) that comprise amyloid β protein assembled into globular non-fibrillar oligomeric structures capable of activating specific cellular processes. The invention also provides methods for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as compounds that block the...

20060178305 - Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations....

20060178308 - Complement inhibitor: The present invention concerns regulation of complement activation, in particular the fluid phase regulation of complement activation, and provides molecules comprising at least complement control protein modules 1-4 of complement factor H, DNA molecules encoding same, their use in the manufacture of a medicament for inhibiting complement activation and methods...

20060178300 - Heterocarpine, a plant-derived protein with anti-cancer properties: The invention relates to a plant-derived protein with anti-cancer properties which binds the human growth hormone-releasing hormone (hGHRH). Said protein, which is obtained from the Pilocarpus Heterophyllus plant, is particularly adapted for preparing a medicament that is intended for the treatment of cancers for which growth is dependant on the...

20060178310 - Intracellular delivery of biological effectors: The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents....

20060178309 - Method for the crystallization of human serum albumin: The present invention relates to the purification and production of human albumin from various sources through crystallization and repeated crystallization. Basic features of the invented process include providing specific reaction conditions and precipitating reagents to maximize albumin crystallization. Solubility diagrams are utilized as the basis for process control of the...

20060178307 - Modulation of nmda receptor currents via orexin receptor and/or crf receptor: This invention pertains to the discoveries that orexin and/or CRF increase NMDAR (N-methyl-D-aspartate receptor)-mediated currents at excitatory synapses onto a subset of dopamine cells in the ventral tegmental area (VTA) in the mammalian brain. The orexin effect can be blocked by an orexin receptor type 1 (OXR1). The CRF effect...

20060178306 - Modulation of the neuroendoctrine system as a therapy for motor neuron disease: The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method...

20060178303 - Potassium channel blockers: The present invention is directed to conopeptides termed conkunitzins and their use for blocking the flow of potassium ions through voltage-gated potassium channels. In view of the Kunitz domain in the conkunitzins, they are also useful for inhibiting platelet aggregation and as protease inhibitors....

20060178304 - Stabilized pharmaceutical peptide compositions: Method for increasing the shelf-life of a pharmaceutical composition for parenteral administration comprising a glucagon-like peptide which is prepared from a peptide product that has been subjected to treatment at a pH above neutral pH....

20060178299 - Therapeutic epitopes and uses thereof: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided....

20060178311 - Control of lactation: The present invention provides three novel peptides identified from cow's milk and further to compositions and methods containing the same for use in the modulation of the milk secretion rate of a lactating cell. Specifically, at least one of the peptides provided by the invention can be used to control...

20060178314 - Methods and compositions for treating atheroma, tumors and other neoplastic tissues: Compositions comprising motexafin gadolinium, as well as methods for using these compositions in the treatment of brain metastases, are described herein....

20060178312 - Process for the production of melagatran: There is provided a process for the production of melagatran, Formula (I) ex vivo, which process comprises the hydrolysis of a compound of Formula II, wherein R is C1-6 alkyl or a benzylic group, to form, in substantially salt-free form, an intermediate compound of formula II followed by reduction of...

20060178313 - Use of a polypeptide for treatment of pruritus in animals: The present invention is directed to a treatment for animal pruritus. One aspect of this invention involves a treatment for animal pruritus comprising one or more polypeptides with an amino acid sequence including KPV (SEQ ID NO: 1), VPK-Ac-CC-Ac-KPV (SEQ ID NO: 5), MEHFRWG (SEQ ID NO: 2), HFRWGKPV (SEQ...

20060178315 - Irreversible cysteine protease inhibitors of legumain: Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects....

20060178316 - Methods of increasing endogenous erythropoietin (epo): The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds....

20060178317 - Methods of increasing endogenous erythropoietin (epo): The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds....

20060178318 - Use of aurora kinase inhibitors for reducing the resistance of cancer cells: This invention relates to the use of anti-cancer agents that inhibit mitotic spindle assembly in target cells, including taxanes such as paclitaxel, and in particular to methods and means for predicting and/or reducing the resistance of cancer cells to such agents. Over-expression of aurora kinases, such as Aurora A, mediates...

20060178319 - Caprazene as novel compound and derivatives thereof, and caprazol as novel compound and derivatives thereof: and a caprazol-1′″-amide-3′″-ester derivative and a caprazol-3′″-ester derivative, etc. from caprazol. Furthermore, an imidazolidinone derivative could be synthesized from the ring-opened product of the 1,4-diazepinone ring of caprazol. The novel caprazene derivative, novel caprazol derivative and novel imidazolidinone derivative now synthesized exhibit excellent antibacterial activities against a variety of bacteria,...

20060178321 - Methods for indentifying compounds that modulate an enzyme involved in reductive carboxylation in a pathogenic microorganism: A method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in a metabolic pathway by inhibiting the conversion of substrate to produce the penultimate or ultimate product particularly by inhibiting the activity of one or more of the enzymes in the pathway, and...

20060178322 - Methods for indentifying compounds that modulate an enzyme involved in riboflavin metabolism in a pathogenic microorganism: A method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in a metabolic pathway by inhibiting the conversion of substrate to produce the penultimate or ultimate product particularly by inhibiting the activity of one or more of the enzymes in the pathway, and...

20060178320 - Methods for indentifying compounds that modulate an enzyme involved in thiamine metabolism in a pathogenic microorganism: A method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in a metabolic pathway by inhibiting the conversion of substrate to produce the penultimate or ultimate product particularly by inhibiting the activity of one or more of the enzymes in the pathway, and...

20060178333 - Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof: The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the...

20060178331 - Antisense oligonucleotides targeting folate receptor alpha, and the use thereof: The invention relates to treatment of cancers and cancerous cells which over-express α folate receptor (FRα) compared to the normal cells of the same tissue. The invention is directed to antisense oligonucleotides which are complimentary to the coding region of FRα, as well as the pharmaceutical compositions made thereof, and...

20060178328 - Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions...

20060178334 - Double-stranded and single-stranded rna molecules with 5 ' triphosphates and their use for inducing interferon: Double-stranded and single-stranded RNA molecules, and their use in methods for inducing interferon are provided. The interferon induction provides anti-viral and other medically useful effects, such as anti-cancer effects. Also provided are methods for reducing or inhibiting interferon induction exhibited by such molecules, particularly siRNA and shRNA molecules produced in...

20060178327 - Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering rna precursors enabling the formation and function of small interfering rna in vivo and in vitro: The use of specially selected sequences from the target gene into designing double stranded or other forms of RNA (siRNA precursors or siRNAp) that enables small interfering RNA (siRNA) from this new invention is delivered for inhibition of cellular gene expression. Diseases may be prevented and treated by this process,...

20060178324 - Lipophilic derivatives of double-stranded ribonucleic acid: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having improved efficiency of inhibition of gene expression, methods of making the dsRNA, and pharmaceutical compositions comprising the dsRNA. The dsRNA comprises an RNA strand (complementary RNA strand) having a region which is complementary to an RNA transcript of at...

20060178337 - Method for diagnosing aplasia of corpus callosum: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial...

20060178335 - Methods and means for obtaining modified phenotypes: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by...

20060178323 - Methods for the treatment of chronic pain and compositions therefor: The invention discloses MMP7 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory effect on MMP7 enzyme activity and/or MMP7 gene expression. The invention...

20060178325 - Modulation of growth hormone receptor expression and insulin-like growth factor expression: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of...

20060178336 - Oral administration of therapeutic agent coupled to transporting agent induces tolerance: The present invention is directed toward a method for the induction of tolerance to a foreign transgene or a self-antigen in an animal host by administration of a composition to an animal host via a natural gastrointestinal pathway. Additionally, the present method can eliminate a pre-existing immune response in an...

20060178332 - Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and...

20060178326 - Ribozyme therapy for the treatment of proliferative skin and eye diseases: As an effective therapy for proliferative skin and eye diseases such as psoriasis and proliferative diabetic retinopathy, this invention provides ribozymes and ribozyme delivery systems which cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, a cyclin, a cell-cycle dependent kinase, a growth factor, or a reductase....

20060178329 - Rnai probes targeting cancer-related proteins: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2,...

20060178330 - Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The...

20060178338 - Use of 5-substituterd nucleosides for reinforcing the apoptotic effect of cytostatic drugs: The invention relates to the use of at least one overexpression inhibitor of DNA repair genes and oncogenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy....

20060178340 - Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 for immune activation or prevention and treatment of cancer and the preparation method thereof: The present invention relates to the soluble glucan oligomer having a M.W. ranging from 1,000 to 10,000 prepared by treating insoluble beta-glucan isolated the cell wall of yeast variant IS2 with commercially available beta-glucan hydrolyzing enzymes. The soluble glucan oligomer showed potent efficacy on promoting immune activity and on inhibiting...

20060178341 - Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 inhibiting the swine influenza (siv) and transmissible gastroenteritis coronavirus (tgev): The present invention relates to the soluble glucan oligomer having a M.W. ranging from 1,000 to 10,000 prepared by treating insoluble beta-glucan isolated the cell wall of yeast variant IS2 with commercially available beta-glucan hydrolyzing enzymes. The soluble glucan oligomer showed potent efficacy on inhibiting activity of influenza virus and...

20060178339 - Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition, and medical treatment material: A crosslinkable polysaccharide derivative which has in the side chain of polysaccharide at least one active ester group reactive with an active hydrogen-containing group and which forms a crosslinked product through covalent bond between the active ester group and the active hydrogen-containing group upon contact with alkaline water. A composition...

20060178342 - Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease: This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer....

20060178343 - Preventive/remedy for obesity: The present invention relates to a preventive/remedy for obesity, which has a hydroxypropylated starch as its active ingredient. Provided are materials for foods, drugs, etc. which can exhibit an effect of preventing/lessening the onset of various lifestyle related diseases, for example, an effect of preventing/ameliorating obesity, or preventing/ameliorating hyperlipidemia; have...

20060178344 - Glucosamine and n-acetylglucosamine and methods of making the same fungal biomass: Glucosamine, N-acetylglucosamine and β-glucan compositions suitable for human or animal consumption or use are disclosed. The glucosamine, N-acetylglucosamine and β-glucan compositions are derived from fungal biomass containing chitin. Various methods of producing glucosamine, N-Acetylglucosamine and β-glucan compositions are also disclosed....

20060178345 - Substituted alcohols useful in treatment of alzheimer's disease: wherein X, R1, R2, R3, RN, R20 and RC are defined herein. The compounds are useful in the treatment or prevention of Alzheimer's disease and more specifically to compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A-beta), a major...

20060178346 - Imines as ion channel modulators: The present invention provides a class of chemical compounds useful in the treatment of sickle cell disease, diseases characterized by unwanted or abnormal cell proliferation and for the treatment of ocular disorders such as glaucoma. The active compounds are tri-(aryl or heteroaryl) methane compounds or analogues thereof which further comprise...

20060178349 - Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid: The present invention is directed to compositions containing a 5-HT1F-specific agonist that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat migraine and headache pain. The invention also includes methods in which these drugs are separately administered to a patient....

20060178348 - Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an nsaid: The present invention is directed to compositions containing an anti-inflammatory compound that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat inflammation and pain, especially headache pain. The invention also includes methods in which these drugs are separately administered to a patient....

20060178347 - Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors: The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The...

20060178350 - 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes: The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes....

20060178351 - Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents: The present invention relates to a method for treating, ameliorating, or preventing immune-mediated disorders in an animal by administering to the animal active vitamin D compounds or mimics thereof The invention further relates to a method for treating, ameliorating, or preventing immune-mediated disorders in an animal by administering to the...

20060178353 - Medicament for preventing and/or treating mammarycarcinoma, containing a steroidal aromatase inhibitor: A method of prophylaxis and/or treatment of mastocarcinoma (i.e., mammary carcinoma) involves the topical application of a therapeutically or prophylactically effective amount of a steroidal aromatase inhibitor locally, and not systemically, to an area of a patient in need of treatment. This local application avoids the side effects associated with...

20060178352 - Use of androgens to reduce the likelihood of acquiring or to treat skin aging: Novel methods of treating or reducing the likelihood of acquiring skin diseases due to age-related androgen deficiency, particularly skin atrophy, loss of collagen, loss of elastic fibers, loss of connective tissue, cellulite, and formation of wrinkles, in susceptible warm-blooded animals including humans involving administration of an androgen or/and a sex...

20060178354 - Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof: The invention relates to the treatment of chronic pain using DHEA or derivatives thereof either alone or in combination with at least one other drug. The invention also includes compositions comprising DHEA or a derivative thereof and a second drug....

20060178355 - Analogs of leucascandrolide a: The present invention describes leucascandrolide analogs of the formula (I), intermediates of the formula (III), pharmaceutical compositions containing the same, methods for preventing cell proliferation, and methods for treating cancers and other proliferative diseases....

20060178356 - Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods: Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituted phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage. They are...

20060178357 - Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases: wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting simultaneously serine and metallo-β-lactamase enzymes, for enhancing the activity of β-lactam antibiotics, and for treating β-lactam resistant bacterial infections in a mammal. The invention also...

20060178358 - Antiprotozoal imidazopyridine compounds: Compounds described by the Formula (I): (I) or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with...

20060178359 - Tricyclic compound, process for producing the same, and use: R2 is (1) an amino group, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atom may be converted to...

20060178361 - Atm inhibitors: R3 is selected from hydroxy and —NRN1RN2, where RN1 and RN2 are independently selected from hydrogen, optionally substituted C1-7 alkyl groups, optionally substituted C3-20 heterocyclyl groups and optionally substituted C5-20 aryl groups, or together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing...

20060178360 - Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain: The present invention concerns novel benzenesulphonamide compounds, defined by formula I and the description, their method of preparation and their use in therapy....

20060178362 - Substituted heterocyle fused gamma-carbolines: or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or...

20060178363 - Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity: The present invention is directed to compounds of the formula (1) Wherein A, B, D, X, Y, n, R1, R3, R4, R5, R15, R16, R17, R18 and the dashed line are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as...

20060178364 - Use of egfr tyrosinkinase inhibitors for treatment of chronic rhinosinusitis: The present invention relates to the use of selected EGFR kinase inhibitors, particularly selected quinazolines, quinolines and pyrimido-pyrimidines, for the treatment of nasal polyposis and chronic rhinosinusitis....

20060178365 - Novel sulfamides: The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists....

20060178366 - Compounds for the treatment of inflammatory disorders: e

20060178367 - Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof: and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are described herein. Pharmaceutical compositions comprising at least one chemical entity of Formula 1, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from...

20060178368 - Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation: Use of a combination of two vitamin compounds, i.e. riboflavin (also known as vitamin B2) and nicotinic acid (also referred to as niacin) or, as an alternative thereto, the corresponding amide, i.e. nicotinamide or niacinamide (also known as vitamin PP) for the systemic treatment of various forms of itching, such...

20060178369 - Cinnamic acid amides: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection....

20060178370 - Ketopiperazine derivatives as bradykinin antagonists: Ketopiperazine derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway....

20060178371 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060178372 - Therapeutic quinoline compounds: Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The...

20060178373 - Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents: The present invention provides novel substituted flavone derivatives which exhibit anti-hyperglycemic and antidyslipedemic activity. The invention also provides a method for controlling type II diabetes and associated hyperlipidemic conditions in a mammal by administering compound of the present invention and compositions containing these derivatives....

20060178374 - Aminoheteroaryl compounds as protein kinase inhibitors: Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers....

20060178375 - Heteroaryloxy nitrogenous saturated heterocyclic derivative: Compound of the formula: (I) [wherein each of X1, X2, and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse...

20060178376 - Novel process for the preparation of hexacyclic compounds: This invention relates to novel processes for the preparation of compounds of the formula [1], wherein R1, R2, R3 and R4 are as defined in the claims and description as well as pharmaceutically acceptable salts thereof. The compounds of the formula [1] are hexacyclic compounds having potent anti-tumor activity....

20060178377 - Azolopyrimidine-based inhibitors of dipeptidyl peptidase iv and methods: i

20060178378 - Novel kinase inhibitors:

20060178379 - Methods of treating patients suffering from movement disorders: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the...

20060178381 - Heterocyclic-substituted phenyl methanones: e

20060178380 - Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines:

20060178382 - Chinazoline derivatives as aurora kinase inhibitors: Quinazoline derivatives of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) formula (I) for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation,...

20060178383 - Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace): The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE....

20060178386 - Dihydroquinazolinones as 5ht modulators: The present application provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and...

20060178385 - Novel adenosine a3 receptor modulators: A class of novel antagonists for the adenosine A3 receptor are disclosed. These compounds are useful as therapeutic agents for a number of diseases and medical conditions that are mediated by the A3 receptor. The compounds of this invention are also useful as diagnostic agents for the A3 receptor....

20060178384 - Novel chemical compounds: This invention relates to newly identified inhibitors of kinases for treating various disorders....

20060178387 - Combined treatment with capecitabine and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and capecitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20060178388 - Phenyl-substituted pyrimidine compounds useful as kinase inhibitors: N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase....

20060178390 - 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders: wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine,...

20060178389 - Use of siramesine in the treatment of cancer: The present invention relates to the treatment of cancer. In particular, the invention provides pharmaceutical compositions comprising siramesine for the treatment of cancer. The invention further provides a method of treatment comprising administering siramesine to a patient suffering from cancer....

20060178392 - Cci-779 polymorph and use thereof: The present invention provides CCI-779 polymorph Form II. This invention also provides processes for preparing CCI-779 polymorph Form II and pharmaceutical compositions including CCI-779 polymorph Form II....

20060178391 - Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives: The present invention is directed to a method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives....

20060178393 - 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same: e

20060178394 - Pharmaceutical compositions comprising apomorphine for pulmonary inhalation: The present invention relates to inhalable formulations of apomorphine or its pharmaceutically acceptable salts or esters for use in treating sexual dysfunction. The present invention also relates to methods for preparing the apomorphine formulations as well as to methods for treatment of sexual dysfunction using said formulations and inhalers including...

20060178395 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided....

20060178396 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided....

20060178397 - Urea derivatives having vanilloid receptor antagonist activity: s

20060178398 - Therapeutic compounds for treating dyslipidemic conditions:

20060178401 - Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof: wherein R1 to R4 are, independent from each other, a hydrogen atom or an optionally substituted alkyl group; E1 is —NR4—; and E2 is an oxygen atom or —NR10—; Q is the group —X—Y-Q′, wherein X and Y are connecting bonds or X is an alkylene or alkenylene group and...

20060178399 - Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient: (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis,...

20060178400 - Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome: h

20060178402 - Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal....

20060178403 - Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto: b

20060178404 - Methods and compositions for controlling ectoparasites: A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one...

20060178405 - Benzopyran compounds, process for preparing the same and their use: The invention relates to the benzopyran compounds of formula (I), or the salts thereof, in which, the bond between 3 and 4 positions is a single or double bond; R1 represents a hydrogen atom or a C1-6 alkyl that can be substituted; R2 represents a hydrogen atom, a C1-6 alkyl...

20060178406 - Process for production of sulfoxide derivatives or salts thereof in the amorphous state: A process for producing sulfoxide derivatives or salts thereof in the amorphous state, characterized by heat-drying solvated crystals of a sulfoxide derivative or a salt thereof represented by the general formula (I): wherein R1 represents a hydrogen atom, a methoxy group, or a difluoromethoxy group; R2 represents a methyl group...

20060178407 - Substituted pyridines and their uses: The present invention is directed to substituted pyridines, methods for their preparation and methods for their use in the treatment and/or prevention of mast cell related conditions....

20060178408 - Nicotinamide derivatives useful as pde4 inhibitors: e

20060178409 - Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors: wherein R1 represents H or lower alkyl, R2 represents H or lower alkyl, R3 represents perfluoro lower alkyl, and X is O or S, or an N-oxide or a tautomer thereof, to salts of such anthranilic acid amides, their N-oxides and their tautomers; processes for the preparation thereof, the application...

20060178410 - Aryl aniline beta2 adrenergic receptor agonists: wherein R1-R13 and w have any of the values described in the specification. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds....

20060178411 - Sulfonimide containing compounds and their use in polymer electrolyte membranes for electrochemical cells: e

20060178412 - Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as ibhibitors of plasminogen activator inhibitor-1 (pai-1):

20060172918 - Composite biomaterials: This invention provides novel composite biomaterials having excellent bioadaptability and bone inductivity and a process for producing the same. The composite biomaterials comprise hydroxyapatite, collagen, and alginate and have microporous structures in which the c-axis of the hydroxyapatite is oriented along the collagen fibers....

20060172919 - Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein a-i and high density lipoprotein: Apolipoprotein A-I-rich Lhigh-density Lipoprotein 2 (HDL2) and Apolipoprotein A-I (ApoA-I) was discovered to inhibit angiogenesis in an in vitro human angiogenesis model, the human placental vein angiogenesis model. Apolipoprotein A-I was able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Application of Apolipoprotein...

20060172921 - Method for identifying active anti-apoptosis compounds: i) cells which express both CD47 and the integrin αvβ3 are cultured, ii) the cells are caused to produce an apoptosis-inducing substance, and/or a substance or substances which induces/induce apoptosis is/are added, iii) the test substance is added, and iv) the apoptosis rate is measured, and to the substances which...

20060172922 - Methods for combating ischemic injury to epithelial organ: A method for enhancing recovery by epithelial cells from ischemia by targeting distinct lesions. The method comprises inhibiting internalization of intercellular junctions, E-cadherin, occludin or other membrane proteins; promoting reuse of preexisting components by targeting for activation specific signaling events during short-term ischemia; inhibiting degradation of E-cadherin or other key...

20060172920 - Oxidised lipids as reversal agents for boronic acid drugs: The use of a lipid in oxidised form for the manufacture of a medicament for therapeutically neutralising (i.e. reducing or substantially destroying the activity of) an organoboronate drug. The lipid may be an HDL hydroperoxide. The drug may be TRI 50c or a salt or prodrug thereof....

20060172923 - Method of activating insulin receptor substrate-2 to stimulate insulin production: The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate...

20060172924 - Methods to enhance hemodynamic stability using oxygen carrying compositions: The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance...

20060172925 - Thio-sirna aptamers: The present invention includes thioaptamers that are partially thio-modified, methods and compositions for the isolation, selection, improvement, characterization and use of RNA and DNA thioaptamers for gene silencing, including degradative and non-degradative interference with translation....

20060172926 - Aplidine for multiple myeloma treatment: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma....

20060172927 - Analogs of human growth hormone-releasing hormone, their preparation and use: Growth hormone-releasing hormone analogs having the amino acid sequence of the formula: Dat-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr10-R11-R12-VAL-Leu-Ala-Gln-Leu-Ser-Ala-R20-R2-Leu-Leu-Gln-Asp-Ile-Nle-Asp-R29-NH2 (I), wherein R11 is hArg, Gab or Gap; R12 is hArg, Orn, Gab or Gap; R20 is hArg, hArg, Gab or Gap; R21 is hArg, Orn, Gab or Gap; R29 is D-Arg, hArg, Gab or Gap; and...

20060172941 - Anti-angiogenic peptides and methods of use thereof: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF,...

20060172940 - Antimicrobial agent: The present application discloses a therapeutic antimicrobial composition comprising mucocidin antimicrobial peptides or analogue or fragments thereof having antimicrobial activity....

20060172930 - Apoptosis-inducing gene and utilization of the same: The object of the present invention is to provide a protein useful for searching an apoptosis-inhibiting substance or an apoptosis-promoting substance, a gene encoding the above protein, a vector comprising the above gene, and a transformant comprising the above vector. The present invention provides an apoptosis-inducing protein of any one...

20060172928 - Composition and method for stabilizing of biomolecules: The present invention relates in general to the field of biotechnology. The invention particularly relates to a composition and process for stabilizing or preserving biological molecules, as well as devices that comprise correspondingly stabilized or preserved biomolecules....

20060172931 - Heparin-binding peptides and uses thereof: Heparin-binding peptides are provided of the formula R1(X1B1B2X2B3X3Y1R2)nR3, R1(X1B1B2B3X2X3B4X4Y1R2)nR3, and C(X1B1B2B3X2X3B4X4)nC; wherein X1, X2, X3, and X4 are independently selected from the group consisting of hydropathic amino acids; B1, B2, B3, and B4 are independently selected from the group consisting of basic amino acids; C is cysteine; Y1 is zero...

20060172946 - Human bikunin: The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof....

20060172945 - Human neutrophil alpha-defensin 4 inhibition of hiv-1: A method to reduce replication of HIV-1, involving administering a therapeutically effective amount of recombinant HNP4 to a subject in need thereof to combat HIV-1 infection. The HNP4 agent may be utilized in pharmaceutical compositions including a pharmaceutically acceptable carrier and an anti-viral agent, e.g., an anti-viral agent, or combination...

20060172937 - Identification of new ny-eso-1 epitopes recognized by cd4+ t-cells: The invention relates to peptides which bind to MHC molecules of either Class I or Class II, and their use. The peptides consist of amino acid sequences found in the NY-ESO-1 molecule....

20060172934 - Method and kit for repairing a defect in bone: Methods and devices are provided for the repair of bone defects. The bone defect repair may be accomplished by minimally invasive means. The bone defect repair may utilize a bone growth promoting substance. The bone growth promoting substance may comprise a carrier material and at least one osteoinductive formulation....

20060172944 - Method of treating eye injury with local administration of a vegf inhibitor: Methods of reducing or treating angiogenesis and/or inflammation associated with eye injury in a subject in need thereof, comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or ameliorating eye injury, particularly acute or subacute corneal injury...

20060172939 - Methods and apparatus for creating particle derivatives of hdl with reduced lipid content: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to...

20060172933 - Natriuretic compounds, conjugates, and uses thereof: Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved...

20060172932 - Novel erythropoietin receptor agonists: Disclosed are novel Erythropoietin receptor agonist proteins, DNAs which encode the Erythropoietin receptor agonist proteins, methods of making the Erythropoietin receptor agonist proteins and methods of using the Erythropoietin receptor agonist proteins....

20060172938 - Peptide inhibitors against seprase: The invention generally relates compositions and methods for the treatment of patients with melanoma and other malignant cancers. The compositions of the present invention are novel peptide sequences that inhibit seprase-mediated cell migration. Said sequences may also be used for diagnostics and library screening protocols....

20060172942 - Process for producing polypeptide mixtures using hydrogenolysis: The subject invention provides for a process for making a mixture of acetate salts of polypeptides, each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising: a) polymerizing N-carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and trifluoroacetyllysine with an initiator...

20060172943 - Restoring vascular function: The invention relates to Tenascin-C and peptides that bind thereto. According to the invention, Tenascin-C or peptides and antibodies that bind thereto can be used to treat or prevent vascular diseases, either alone or in combination with therapeutic agents or cells that have cardioplastic potential....

20060172935 - Screening and therapeutic methods for treating circadian rhythm disorders: The invention provides a method for screening for a compound for modulating circadian rhythm. The method involves (a) providing a compound that is a Prokineticin 2 (PK2) receptor antagonist or agonist; and (b) determining the ability of the compound to modulate one or more indicia of circadian rhythm function, wherein...

20060172936 - Sulfonamide inhibitors of aspartyl protease: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and...

20060172929 - Use of natriuretic peptides for the treatment of stature disorders related to the shox gene: The invention relates to the use of natriuretic peptides (ANP or BNP) for the preparation of pharmaceutical compositions for the treatment of short stature in a subject being suspected of having a genetic defect in the human SHOX gene. Further, the invention relates to use of natriuretic peptides in combination...

20060172948 - Gamma-carboxyglutamate containing conopeptides: The invention relates to γ-carboxyglutamate containing conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding...

20060172947 - Physiologically active peptides and drugs containing the same: A peptide having any one of the amino acid sequences of SEQ ID NO: 1 or 13, preferably a peptide having any one of the amino acid sequences of SEQ ID NOS: 2 to 9 or a peptide having any one of the amino acid sequences of SEQ ID NOS:...

20060172949 - Compositions for preventing and treating digestive organs diseases: The present invention provides a composition for safely and effectively preventing and treating digestive organs diseases, particularly, gastric ulcer, duodenal ulcer, gastritis, diarrhea, enteritis and the like. There is also provided a composition having a novel mechanism of action in order to solve the problems which was difficult to be...

20060172951 - Age related macular degeneration and cutaneous signs of mercury toxicity: A method is provided for treating age related macular degeneration and Grover's disease by administering a safe and effective amount of a chelation agent to a person who would benefit from such treatment. Of particular effectiveness are chelation agents with sulfur atoms and which through the sulfur bind to mercury....

20060172952 - Aza-peptide epoxides: Methods for treatment and/or prevention of nerve degeneration in mammals using aza-peptide epoxide caspase inhibitors are provided. Aspects of the present disclosure include aza-peptide epoxide compositions to treat or prevent diseases, for example stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuropathies, Huntington's disease, dentatorubropallidoluysian atrophy, spinocerebellar atrophies, spinal bulbar muscular...

20060172950 - Hepatitis c virus inhibitors: t

20060172954 - Systems and methods for dextrose containing peritoneal dialysis (pd) solutions with neutral ph and reduced glucose degradation product: The invention provides container systems, kits and methods for peritoneal dialysis (PD) solutions. Such a system, for example, includes a first compartment that contains a Pt) osmotic agent and a second compartment that contains a PD buffer agent. The compartments maintain their respective contents separately from one another for purposes...

20060172953 - Treatment of benign prostatic hyperplasia using energolytic agents: The invention provides a method for treatment or prophylaxis of benign prostatic hyperplasia by administration of an agent that interferes with energy metabolism, particularly the production of ATP and NADH/NADPH, in prostate epithelial cells....

20060172955 - Antibiotic/benzoyl peroxide dispenser: Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife...

20060172956 - Compositions and methods for the treatment of arthritis: The present invention provides compositions, combination of medicaments, and methods for the treatment of certain conditions such as arthritis, and in particular, reactive arthritis, osteoarthritis, and bursitis, among others....

20060172957 - Antisense modulation of integrin beta 4 binding protein expression: Antisense compounds, compositions and methods are provided for modulating the expression of Integrin beta 4 binding protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Integrin beta 4 binding protein. Methods of using these compounds for modulation of Integrin beta 4 binding protein expression and...

20060172966 - Immunostimulatory g, u-containing oligoribonucleotides: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening...

20060172964 - Methods for reducing amyloid beta levels: The present invention relates to the treatment and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for reducing production of β amyloid by reducing or preventing the binding of amyloid precursor protein (APP) to an X11 adaptor protein. Also provided are methods for...

20060172962 - Modification of myd88 splicing using modified oligonucleotides: Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided....

20060172958 - Phospholipid scramblase 3: Phospholipid scramblase 3 (PLS3) is a newly recognized member of a family of proteins responsible for phospholipid translocation between two lipid compartments. A novel isoform of PLS3 is identified and characterized herein. The function of PLS3 in mitochondria was disrupted, yielding an inactive mutant PLS3(F258V). Cells transfected with PLS3(F258V) exhibited...

20060172961 - Rnai inhibition of serum amyloid a for treatment of glaucoma: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression....

20060172963 - Rnai-mediated inhibition of ocular hypertension targets: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by...

20060172965 - Rnai-mediated inhibition of ocular targets: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by...

20060172959 - Selected rna motifs to include cell death and/or apoptosis: The present application is directed to the use of dsRNA and/or ssRNA for the purpose of inducing apoptosis or cell death in proliferating cells. Specifically, low molecular weight and high molecular weight dsRNA and ssRNA are shown to induce apoptosis and/or cell death in proliferating cells, to arrest proliferation of...

20060172960 - Therapy and diagnosis of conditions related to telomere length and/or telomerase activity: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric...

20060172968 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect: t

20060172967 - Method for producing alkyl-esterified glycosaminoglycan: A method for producing an alkyl-esterified glycosaminoglycan, which comprises the step of allowing a trialkylsilyldiazoalkane to act on a glycosaminoglycan to perform alkyl-esterification of carboxyl groups of the glycosaminoglycan, and an alkyl-esterified glycosaminoglycan having a property that it is not substantially degraded by a glycosaminoglycan degrading enzyme such as hyaluronidase...

20060172969 - Aqueous pharmaceutical compositions: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time...

20060172970 - Methods for treatment and management of lung cancer using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or...

20060172971 - Protection against and treatment of hearing loss: The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss....

20060172972 - Formulation and method for administration of ophthalmologically active agents: A method and formulation are provided for the administration of ophthalmologically active agents. In one embodiment, the method and formulation provided are for the treatment of medical conditions associated with the formation and/or deposition of macromolecular aggregates, particularly those associated with adverse ocular conditions. In another embodiment, the method and...

20060172974 - Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine: The instant disclosure provides crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, salts and solvates thereof. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s)....

20060172973 - Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase: A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as...

20060172975 - Ibandronate polymorph: The present invention relates to a new polymorph crystal form of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1 1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with the following formula...

20060172976 - Ibandronate polymorph: The present invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl) amino-1-hydroxypropane -1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with the following formula...

20060172977 - Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage: Methods and compositions are provided for preventing, reducing and reversing ischemic neuronal damage related to congenital and acquired ophthalmologic conditions such as macular degeneration, retinitis pigmentosa, optic neuritis, neuroretinitis, Lebers congenital amaurosis, Stargardts disease, Parkinson's disease, diabetic retinopathy, idiopathic senile vision loss, uveitis, edema and ocular surgery. An amount of...

20060172978 - Method of neutralising organoboronates with acids: The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt...

20060172979 - New use of gabab receptor agonists: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough....

20060172980 - Combretastatin a-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4....

20060172981 - Fungicidal combinations of active substances: o

20060172982 - Formulation comprising tetracycline or derivative and method of treating or preventing infections and inflammatory conditions: Therapeutic composition and method for treating or preventing various conditions and diseases, including inflammatory conditions, allergies, particularly seasonal allergies, and the common cold. In a preferred embodiment, the therapeutic composition is a formulation comprising an antibiotic, preferably a tetracycline, most preferably doxycycline, which has not been chemically modified to eliminate...

20060172983 - Functionalized drugs and polymers derived therefrom: where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone moiety), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O— (glycolic...

20060172985 - Internal 1, 15-lactones of fluprostenol and related prostaglandin f2a analogs and their use in the treatment of glaucoma and intraocular hypertension: Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction...

20060172984 - Methods and compositions of novel triazine compounds: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that...

20060172986 - Polycarboxylated porphyrins and use thereof in treatment of metal toxicities: Metal binding polycarboxylated porphyrins, their precursors, or cofactors in the porphyrin biosynthetic pathway, are administered to individuals determined to be subject to or predisposed to a polycarboxylated porphyrin-binding metal toxicity to increase the level of the metal-binding polycarboxylated porphyrin in the individual....

20060172987 - Amoxicillin trihydrate: The present invention relates to a product of amoxicillin trihydrate, having a free water content of less than 0.1 wt. %, preferably less than 0.07 wt. %, more preferably less than 0.05 wt. %, measured at an equilibrium relative humidity of 30% and at a temperature of 25° C. The...

20060172988 - Azetidine compounds: The present invention relates to a compound of the general formula (I) wherein Het is an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring having at least one nitrogen atom; R1 is hydrogen, hydroxy, C1-C4 alkyl, C3-C4 C2-C4 alkenyl or C2-C4 alkynyl; R2 and R3 is each and independently...

20060172989 - Aminoalkoxyphenyl indolone derivatives: This invention is directed to aminoalkoxyphenyl indolone derivatives which are ligands at the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective...

20060172990 - Antibacterial agents: Compounds of formula (I) have antibacterial activity, wherein Q represents —N(OH)CH(═O) or —C(═)NH(OH); Y represents —C(═O)—, —C(═S)—, —S(═O)—, or —SO2—; R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of formula —N(OH)CH(═O), a hydroxy, C1-C6 alkoxy, C1-C6...

20060172991 - Use of inhibitors of jun n-terminal kinases to treat glaucoma: Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection....

20060172992 - Therapeutic agent for overactive bladder resulting from cerebral infarction: An agent for treating overactive bladder resulting from cerebral infarction, comprising administrating a compound having a cholinesterase inhibitory activity or a pharmacologically acceptable salt thereof....

20060172993 - Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease: Galantamine has be used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease. Neuropsychiatric disorders are often associated with Alzheimer's disease. It is demonstrated that galantamine is also effective in reducing or stabilizing the incidence...

20060172994 - Compounds useful as chemokine receptor antagonists: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone...

20060172995 - Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction:

20060172997 - Combinations of inhibitors of reverse transcriptase and inhibitors of virus-encoded dna polymerase: A method for treating viral diseases which are caused by DNA viruses is described comprising administering an effective amount of at least one inhibitor of reverse transcriptase (RTI) in combination with at least one inhibitor of viral DNA polymerase, wherein the at least one RTI and the at least one...

20060172996 - Method of preventing relapse in the abstinent substance dependent individual: A method of preventing a relapse in the abstinent substance dependent person. The method involves the use of the medication Flumazenil in a spray delivery device and to teach the person to self-administer the medication by spraying the medication into either the nasal passage, the buccal mucosol membranes or the...

20060172998 - Method of preventing relapse in the abstinent substance dependent individual: A method of preventing a relapse in the abstinent substance abuse dependent person. The method involves the use of the medication of Flumazenil in a nasal spray device and to teach the person to self-administer the medication by spraying the medication into the nasal passage whenever the need and the...

20060172999 - Tetrahydropyran compounds as tachykinin antagonists: The present invention relates to the compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and W are as defined herein, and pharmaceutically acceptable salts thereof; the compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis...

20060173000 - Substituted indolepyridinium as anti-infective compounds: their N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(═O), C(═O)OH, C1-4alkyloxyC(═O), C1-4alkylC(═O), mono- or di(C1-4alkyl)aminoC(═O), arylaminoC(═O), N-(aryl)-N—(C1-4alkyl)aminoC(═O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het, or Het2; R2 is H, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl...

20060173001 - Novel compounds for use in weight loss and appetite suppression in humans: Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, obtainable from monocotyledonous plants, orby chemical synthesis, have been found to act as weight loss agents, appetite suppressants, mood enhancers and adjunctive therapy for...

20060173002 - Heteroaryl compounds as p2y1 receptor inhibitors: The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity....

20060173003 - Substituted quinazolin-4-ylamine analogues: Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for...

20060173004 - 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives: A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases....

20060173006 - Compounds for inflammation and immune-related uses: c

20060173005 - Process for preparing nitrooxyderivative of naproxen: wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is...

20060173007 - Compounds, compositions, and methods: 1,2,4-Triazin-5-ones useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed....

20060173008 - New pyridazin-3(2h)-one derivatives: Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4. R1, R2 and R4 are organic radicals, R3 is a cyclic group, and R5 is an ester or an aryl or heteroaryl group....

20060173009 - Agent inducing increase in bone mass: Osteoporosis and the like metabolic bone diseases have a high frequency of causing lumbago and the like pains and bone fracture, due to lowering of the bone strength caused by the reduction of bone mass. Accordingly, great concern has been directed toward the creation of a drug which can increase...

20060173010 - Modulators of tnf-alpha signaling: The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas:...

20060173011 - Treatment of inflammatory disorders with praziquantel: Methods of treating and/or preventing disorders mediated by one or more of TNF-α, NF-κB, IKK-α, IKK-β, ATF-2 and p38 kinase by administration of praziquantel, or a pharmaceutically acceptable salt, prodrug, ester or amide thereof. These disorders include inflammatory disorders such as autoimmune diseases....

20060173012 - Novel piperazines: to the use of these compounds in the preparation of pharmaceutical compositions, to pharmaceutical compositions comprising the compounds, and to methods of treatment employing these compounds or compositions. The compounds show a high and selective binding affinity for the histamine H3 receptor, indicating histamine H3 receptor antagonistic, inverse agonistic or...

20060173013 - Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity: The present invention is directed to compounds of the formula I: I (wherein R1, R2, R3, R4, R5, R6, X, Z and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2....

20060173014 - Nobel compounds having selective inhibiting effect at gsk3: The present invention relates to new compounds, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective inhibiting effect at GSK3....

20060173015 - Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms: or a pharmaceutically acceptable form thereof, as dual selective α1a/α1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as...

20060173016 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060173017 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,...

20060173018 - Quinazolines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders....

20060173019 - Heteroaryl sulfonamides and ccr2: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as...

20060173020 - 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives: m

20060173021 - Compounds for inflammation and immune-related uses:

20060173023 - 2-(bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation: Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway....

20060173024 - Compositions and methods for treating heart failure: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure....

20060173022 - Heterocyclic amides, method for the production thereof, substances containing said heterocyclic amides, and use thereof as pesticides: wherein: A is CH or N; Y is O or S; n is 0 or 1; R1 is (C1-C4)-haloalkyl; R2 and R3 are identical or different and are hydrogen, (C1-C4)-alkyl, (C1-C4)-haloalkyl or halogen; R4 is hydrogen, (C1-C10)-alkyl, (C3-C10)-cycloalkyl, (C3-C10)-alkenyl or (C3-C10)-alkynyl, where in the alkyl, cycloalkyl, alkenyl or alkynyl groups...

20060173025 - 2-substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole &lsqb;2,3-d&rsqb;pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof: The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of...

20060173026 - 8-n-substituted-2h-isothiazolo[5,4-b]quinolizine-3,4-diones and related compounds as antiinfective agents: Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents....

20060173027 - Spirocvclic piperidines as mch1 antagonists and uses thereof: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective...

20060173028 - Therapeutic and/or preventive agent for chronic skin disease: The present invention provides a therapeutic and/or preventive agent for chronic skin diseases which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1′-cyclopentane] or a pharmaceutically acceptable salt thereof as an active ingredient....

20060173029 - Oxycodone hydrochloride having less than 25 ppm 14- hydroxycodeinone: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone....

20060173030 - Antitumoral analogs of lamellarins: New lamellarins are provided of the general formula III wherein X is selected from the group consisting of N, O and S; wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from the group consisting of H, OH, OR′, SH, SR′, SO2R′, NHR′, N(R′)2,...

20060173032 - Isolation and structure of cribrostatin 6: Cribrostatin 6, a dark blue cancer cell growth inhibiting constituent of the Republic of Maldives marine sponge Cribrochalina sp. has been isolated, and its structure (shown below) elucidated, based on a combination of RMS, high field (500 MHz, HMBC, and GOESY experiments) 15N, 1H- and 13C NMR, and X-ray crystal...

20060173031 - Therapeutic agent for schizophrenia: Provision of a pharmaceutical agent useful for the treatment of schizophrenia. As a solving means, a therapeutic agent for schizophrenia containing a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative, an enantiomer thereof, an acid addition salt thereof or a hydrate or solvate thereof as an active ingredient is provided....

20060173033 - Use of rapamycin and rapamycin derivatives for the treatment of bone loss: The present invention relates to a new use of rapamycin and rapamycin derivatives....

20060173034 - Novel 4-anilinoquinoline-3-carboxamides: The present invention relates to novel compounds which are JAK3 Kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them....

20060173035 - 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake: There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from...

20060173036 - Imidazopyridine derivatives as melanocortin receptor agonists: Derivatives of imidazopyridine which have a good affinity for certain sub-types of melanocortin receptors, in particular MC4 receptors and are useful for treating pathological states and diseases in which one or more melanocortin receptors are involved and pharmaceutical compositions containing said products....

20060173037 - Aminophenyl derivatives as selective androgen receptor modulators: r

20060173038 - Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic: The present invention relates to a method for the prevention or the treatment of heart failure comprising administration of a therapeutically effective amount of an anticholinergic 1, medicaments for the prevention or treatment of heart failure comprising one or more, preferably one anticholinergic 1, and methods for the preparation of...

20060173039 - 4-(substituted aryl)-5-hydroxyisoquinolinone derivative: e

20060173040 - Arylamides: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis of diseases in people or animals, especially diseases of bacterial infection....

20060173042 - Process for the preparation of fexofenadine: The present invention relates to a process for the preparation of cyclopropyl keto a,a-dimethylphenyl acetic acid of structural Formula I, and to the use of this compound as an intermediate for the preparation of an antihistamine, fexofenadine....

20060173044 - Substituted propargylamines: c) R2 and R3 together with the nitrogen atom to which they are attached form N-heteroaryl or N-heterocyclyl, unsubstituted or mono- or polysubstituted by identical or different radicals, if appropriate also as N-oxide or salt, as pesticide against arthropods and helminths for protecting plants and animals....

20060173041 - Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors: A compound of formula (1), wherein B is an ortho substituted monocyclic aryl or heteroaryl group or a bicyclic aryl or heteroaryl group; useful in the inhibition of one or more metalloproteinases, and in particular TACE....

20060173043 - Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same: The present invention is related to novel use of 2-oxo-heterocyclic compounds having anticancer activity and the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the cancer disease comprising lung cancer, bone cancer, pancreatic cancer, skin cancer,...

20060173045 - Preventative or remedy for grinding: The present invention provides a preventive or therapeutic agent for bruxism or bruxism-related diseases that contains as an active ingredient at least one selected from the group consisting of proton pump inhibitors, histamine H2 receptor antagonists, and acid pump antagonists. Examples of the proton pump inhibitors include rabeprazole, omeprazole, esomeprazole,...

20060173046 - Hydroxypyridine cgrp receptor antagonists: The present invention is directed to compounds of Formula I: I (where variables R1, R2, R3 and R4 are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as headache, migraine and cluster headache. The...

20060173047 - Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics: The invention relates to the field of blood coagulation, more particularly, to novel compounds of general formula (I), to a method for producing said compounds and to their use as active ingredients in medicaments for the prevention and/or the treatment of diseases....

20060173048 - Imidazole derivatives: e

20060173049 - Amino-pyridines as inhibitors of beta-secretase:

20060173050 - Inhibitors of c-jun n-terminal kinases: The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3....

20060173051 - Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof: Thiocarbonate and thiocarbamate derivatives of 4-demethylpenclomedine are provided along with pharmaceutical compositions containing them and use for treating cancer. A method for preparing the derivatives is also provided....

20060173052 - Use of the non-opiate analgesic drug flupirtine of the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome: The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of...

20060173053 - Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents: Basic esters of fatty alcohols of the general formula: R1-O—CO-A or pharmaceutically acceptable salts thereof, wherein R1 is C12-C24 alkyl or C10-C24 alkenyl, and A is a residue containing at least one acyclic or cyclic amino group and/or at least one heteroaromatic ring containing a tertiary or quaternary nitrogen atom,...

20060173054 - Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase: s

20060173055 - Pyrrole compounds useful as kinase inhibitors: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds, processes for making the compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders....

20060173056 - Proline derivatives and use thereof as drugs: e

20060173057 - Methods of treating factor viia-associated conditions with compounds having an amine nucleus:

20060173059 - Agent for preventing or treating portal hypertension: wherein R1 represents a group capable of forming an anion, etc.; X represents a bond or a spacer; n is an integer of 1 or 2; ring A is benzene ring which may be further substituted; R2 represents a group capable of forming an anion, etc.; and R3 represents a...

20060173058 - Kcnq channel modulating compounds and their pharmaceutical use: This invention relates to novel compounds useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith....

20060173060 - Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems: Biocompatible microparticles include an ophthalmically active alpha-2 adrenergic receptor agonist and a biodegradable polymer. The microparticles include oil-in-water emulsified microparticles which can be used to treat an ocular condition, such as glaucoma....

20060173061 - New beta-agonists, processes for preparing them and their use as pharmaceutical compositions: o

20060173062 - Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis: The instant invention is directed to the use of cyclooxygenase-2 selective inhibitors to treat or prevent endometriosis; the use of cyclooxygenase-2 selective inhibitors to prevent, retard and/or reverse the development of endometriotic lesions in patients at risk for the development of such lesions; the use of cyclooxygenase-2 selective inhibitors to...

20060173064 - (-)-1-(3,4-dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders: The present invention relates to (−)-1-(3,4-dichlorophenyl )-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In certain embodiments the methods and compositions of the invention are effective for treating attention-deficit disorder,...

20060173063 - Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them: The present invention relates to exo-(t-butyl 2R(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate (formula 1) a novel compound, and the process for the preparation thereof, and novel intermediates therein....

20060173065 - Functionalized phenolic esters and amides and polymers therefrom: —COCH2O(CH2CH2O)n— where n is an integer between 2 and 24, inclusive; and R′ is either hydrogen or a benzyl or an alkyl group, the alkyl group being either straight-chained or branched. The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the...

20060173066 - Remedy for diabetes: An object of the present invention is to provide a therapeutic agent for diabetes mellitus or insulin resistance improving agent, or to provide foods and drinks, food and drink additives, and feeds or feed additives for treating diabetes mellitus or improving insulin diabetes. In order to achieve such an object,...

20060173067 - Small molecules for the treatment of atherosclerosis: This invention provides novel small molecules that ameliorate one or more symptoms of atherosclerosis. The small molecules are highly stable and readily administered via an oral route. The small molecules are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and...

20060173068 - Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same: The invention provides an amorphous form of Dorzolamide hydrochloride, processes for the preparation of amorphous Dorzolamide hydrochloride, processes for making Form II from amorphous Dorzolamide HCl, a crystalline form of Dorzolamide hydrochloride, Form IV, process for making Form IV, and pharmaceutical compositions of amorphous Dorzolamide hydrochloride, Dorzolamide hydrochloride Form II...

20060173071 - Mast cell stabilizers used to inhibit laminitis: The invention provides the use of mast cell stabilizers, which composition inhibits excess chemical release such as the mediator of laminitis, histamine, from mast cells for the prevention and/or treatment of laminitis. Mast cell stabilizers can be administered by way of inhalation, oral, subcutaneous, intramuscular or topical. Mast cell stabilizers...

20060173070 - Method of enhancing motor function: This invention relates to a method for enhancing physical activities by administering catechins. The combined use of catechin ingestion and exercise makes it possible to promote the oxidation of fat and hence, to inhibit obesity, liver enlargement and diabetes....

20060173069 - Therapeutic agent for hyperpotassemia and bone disease: i

20060173072 - Novel shogaol compound and tyrosinase activity inhibitor comprising the compound:

20060173073 - Microfine zinc-glycerol complexes: The present invention relates in part to a method of manufacturing zinc-glycerol complexes and the zinc-glycerol complexes so produced, which unexpectedly results in microfine zinc-glycerol complex particles which have a mean particle length (i.e., major axis) of less than about 1.0 micron. The zinc-glycerol complex particles of the invention also...

20060173074 - Treatment of restless legs syndrome: A method for the treatment of restless legs syndrome in a patient using a combination of a COMT-inhibitor, a decarboxylase inhibitor and a dopamine precursor....

20060173075 - P-(sulfonyl) aryl and heteroarylamines-as anti-inflammatory agents: This invention relates to anti-inflammatory and analgesic compounds, especially to certain p-(sulfonyl)phenyl amino derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds....

20060173076 - Antibiotic/benzoyl peroxide dispenser: Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife...

20060173077 - Surgical method: An irrigation technique that can be used to increase the flow of fluid through the trabecular meshwork and to deliver a therapeutic agent or compound directly into the trabecular meshwork. Pulses of relatively high pressure irrigating balanced salt solution containing a therapeutic agent or compound can be directed at the...

20060173078 - Method of treatment or prophylaxis of symptoms of herpes viral infection: A method providing the treating or prophylaxis of one or more symptoms of viral infection. The method involving the administration of citrate and/or succinate salts. The present invention also encompasses the use of citrate and/or succinate salts for the treatment of prevention of lesions or blisters, or other symptoms of...

20060173079 - Compositions and methods for improving the condition of patients suffering from copd and other diseases: A food supplement of therapeutic composition is provided suitable for the treatment or prophylaxis of COPD and other acute or chronic diseases in a mammal, especially a human being, comprising at least one of glutamate, other than mono sodium glutamate, and a precursor of glutamate selected from the group consisting...

20060173080 - Methods of modulating tnf using bupropion: A new method employing a known compound, bupropion hydrochloride (.±.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride, and its analogues, in a new use for the treatment of TNF-related disorders is described....

20060173081 - Treating morning migraines with propranolol: This invention relates to a method for preventing and treating morning migraine headaches. Pursuant to this method, a therapeutic amount of β-adrenergic-blocking agent is administered nightly to a person that suffers from migraine attacks such that the blocking agent is first released during morning hours when the person is most...